



## Clinical trial results:

### A Multi-Centre Randomised Clinical Trial of Biomarker-Driven Maintenance Treatment for First-Line Metastatic Colorectal Cancer (MODUL)

#### Summary

EudraCT number	2014-001017-61
Trial protocol	IT GB DE PT DK SK NL FR SE BE GR ES SI CY
Global end of trial date	24 March 2021

#### Results information

Result version number	v3 (current)
This version publication date	05 April 2024
First version publication date	12 June 2020
Version creation reason	

#### Trial information

##### Trial identification

Sponsor protocol code	MO29112
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02291289
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	F. Hoffmann-La Roche AG
Sponsor organisation address	Grenzacherstrasse 124, Basel, Switzerland, CH-4070
Public contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com
Scientific contact	F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG, 41 616878333, global.trial_information@roche.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 March 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 May 2019
Global end of trial reached?	Yes
Global end of trial date	24 March 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate progression free survival (PFS).

Protection of trial subjects:

All study subjects were required to read and sign an Informed Consent Form.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	17 April 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 8
Country: Number of subjects enrolled	Belgium: 44
Country: Number of subjects enrolled	Bosnia and Herzegovina: 13
Country: Number of subjects enrolled	Brazil: 61
Country: Number of subjects enrolled	Denmark: 18
Country: Number of subjects enrolled	Egypt: 10
Country: Number of subjects enrolled	France: 75
Country: Number of subjects enrolled	Germany: 184
Country: Number of subjects enrolled	Greece: 47
Country: Number of subjects enrolled	Italy: 163
Country: Number of subjects enrolled	Mexico: 31
Country: Number of subjects enrolled	Netherlands: 32
Country: Number of subjects enrolled	Poland: 24
Country: Number of subjects enrolled	Portugal: 17
Country: Number of subjects enrolled	Korea, Republic of: 31
Country: Number of subjects enrolled	Russian Federation: 20
Country: Number of subjects enrolled	Serbia: 10
Country: Number of subjects enrolled	Slovakia: 2
Country: Number of subjects enrolled	Spain: 113
Country: Number of subjects enrolled	Sweden: 8
Country: Number of subjects enrolled	Türkiye: 40
Country: Number of subjects enrolled	United Kingdom: 90

Country: Number of subjects enrolled	Slovenia: 3
Worldwide total number of subjects	1044
EEA total number of subjects	730

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	614
From 65 to 84 years	424
85 years and over	6

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

To be eligible for the study, subjects provided a primary tumour sample for biomarker assessment. This sample came from the original diagnosis and was used for the biomarker assessment which determined treatment assignment during the Maintenance Treatment Phase.

### Period 1

Period 1 title	Induction Treatment Phase
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Cohort 1: Induction Phase (IP)

Arm description:

Included participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.

Arm type	Induction Treatment
Investigational medicinal product name	5-fluorouracil (5-FU), leucovorin calcium (LV), and Oxaliplatin (FOLFOX)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Administered per the Investigator's discretion in accordance with locally approved prescribing information.

Investigational medicinal product name	5-FU/LV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1600-2400 mg/m<sup>2</sup> 5-FU via 46-hour IV infusion in combination with 400 mg/m<sup>2</sup> LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression or death from any cause, whichever occurs first.

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

<b>Arm title</b>	Cohort 2 (IP)
------------------	---------------

**Arm description:**

Included participants with BRAFwt. All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.

Arm type	Induction Treatment
Investigational medicinal product name	5-fluorouracil (5-FU), leucovorin calcium (LV), and Oxaliplatin (FOLFOX)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Administered per the Investigator's discretion in accordance with locally approved prescribing information.

Investigational medicinal product name	5-FU/LV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

1600-2400 mg/m<sup>2</sup> 5-FU via 46-hour IV infusion in combination with 400 mg/m<sup>2</sup> LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression or death from any cause, whichever occurs first.

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

<b>Arm title</b>	Cohort 3 (IP)
------------------	---------------

**Arm description:**

Included participants with human epidermal growth factor receptor 2 positive (HER2+). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.

Arm type	Induction Treatment
Investigational medicinal product name	5-fluorouracil (5-FU), leucovorin calcium (LV), and Oxaliplatin (FOLFOX)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Administered per the Investigator's discretion in accordance with locally approved prescribing information.

Investigational medicinal product name	5-FU/LV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

1600-2400 mg/m<sup>2</sup> 5-FU via 46-hour IV infusion in combination with 400 mg/m<sup>2</sup> LV via 2-hour

infusion on Day 1 of every 2-week cycle until disease progression or death from any cause, whichever occurs first.

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

<b>Arm title</b>	Cohort 4 (IP)
------------------	---------------

Arm description:

Included participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFWT); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.

Arm type	Induction Treatment
Investigational medicinal product name	5-fluorouracil (5-FU), leucovorin calcium (LV), and Oxaliplatin (FOLFOX)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Administered per the Investigator's discretion in accordance with locally approved prescribing information.

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Investigational medicinal product name	5-FU/LV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1600-2400 mg/m<sup>2</sup> 5-FU via 46-hour IV infusion in combination with 400 mg/m<sup>2</sup> LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression or death from any cause, whichever occurs first.

Number of subjects in period 1	Cohort 1: Induction Phase (IP)	Cohort 2 (IP)	Cohort 3 (IP)
Started	93	635	6
Completed	63	460	5
Not completed	30	175	1
Consent withdrawn by subject	-	24	-
Non-Compliance	-	1	-
Physician decision	-	3	-
Adverse Event	-	3	-
Death	25	111	1
Reason Not Specified	-	4	-
Lost to follow-up	1	12	-
Missing	4	14	-
Protocol deviation	-	3	-

Number of subjects in period 1	Cohort 4 (IP)
Started	310
Completed	135
Not completed	175
Consent withdrawn by subject	18
Non-Compliance	1
Physician decision	1
Adverse Event	1
Death	82
Reason Not Specified	7
Lost to follow-up	9
Missing	54
Protocol deviation	2

## Period 2

Period 2 title	Maintenance Treatment Phase
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Cohort 1: 5-FU/LV,cetuximab,vemurafenib
Arm description: Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFMut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) received 1600-2400 milligrams per square meter (mg/m <sup>2</sup> ) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m <sup>2</sup> LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m <sup>2</sup> cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.	
Arm type	Experimental
Investigational medicinal product name	Cetuximab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details: 500 mg/m <sup>2</sup> via IV infusion on Day 1 of every 2-week cycle	
Investigational medicinal product name	5-FU/LV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details: 1600-2400 mg/m <sup>2</sup> 5-FU via 46-hour IV infusion in combination with 400 mg/m <sup>2</sup> LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first.	
Investigational medicinal product name	Vemurafenib
Investigational medicinal product code	
Other name	RO5185426
Pharmaceutical forms	Solution for infusion, Film-coated tablet
Routes of administration	Oral use
Dosage and administration details: 960 mg vemurafenib BID by mouth	
<b>Arm title</b>	Cohort 1 Control: 5-FU/LV or capecitabine, bevacizumab
Arm description: Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.	
Arm type	Active comparator
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details: 5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information	
Investigational medicinal product name	5-FU/LV or capecitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details: Per Investigator's discretion: 1600-2400 mg/m <sup>2</sup> administered via 46-hour IV infusion on Day 1 of	



every 2-week cycle and LV 400 mg/m<sup>2</sup> administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m<sup>2</sup> twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

<b>Arm title</b>	Cohort 2: 5-FU/LV or capecitabine, bevacizumab, atezolizumab
------------------	--

**Arm description:**

Participants with BRAFwt received fluoropyrimidine (1600-2400 mg/m<sup>2</sup> 5-FU via 46-hour IV infusion in combination with 400 mg/m<sup>2</sup> LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m<sup>2</sup> twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.

Arm type	Experimental
Investigational medicinal product name	5-FU/LV or capecitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Per Investigator's discretion: 1600-2400 mg/m<sup>2</sup> administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m<sup>2</sup> administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m<sup>2</sup> twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

<b>Arm title</b>	Cohort 2 Control: 5-FU/LV or capecitabine, bevacizumab
------------------	--

**Arm description:**

Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

Arm type	Active comparator
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Investigational medicinal product name	5-FU/LV or capecitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Per Investigator's discretion: 1600-2400 mg/m<sup>2</sup> administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m<sup>2</sup> administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m<sup>2</sup> twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

<b>Arm title</b>	Cohort 3: capecitabine, trastuzumab, pertuzumab
------------------	---

**Arm description:**

Participants with human epidermal growth factor receptor 2 positive (HER2+) received 1000 mg/m<sup>2</sup> twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.

Arm type	Experimental
Investigational medicinal product name	Capecitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

**Dosage and administration details:**

1000 mg/m<sup>2</sup> twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks

Investigational medicinal product name	Pertuzumab
Investigational medicinal product code	
Other name	RO4368451
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle

Investigational medicinal product name	Trastuzumab
Investigational medicinal product code	
Other name	Herceptin; RO0452317
Pharmaceutical forms	Solution for infusion, Powder and solvent for concentrate for solution for infusion
Routes of administration	Intravenous use

**Dosage and administration details:**

Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle

<b>Arm title</b>	Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab
------------------	---

**Arm description:**

Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

Arm type	Active comparator
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:  
5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Investigational medicinal product name	5-FU/LV or capecitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Per Investigator's discretion: 1600-2400 mg/m<sup>2</sup> administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m<sup>2</sup> administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m<sup>2</sup> twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

<b>Arm title</b>	Cohort 4: Cobimetinib,atezolizumab
------------------	------------------------------------

Arm description:

Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFWT); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) received 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.

Arm type	Experimental
Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	RO5541267
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg

Investigational medicinal product name	Cobimetinib
Investigational medicinal product code	
Other name	RO5514041
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

60 mg orally once daily for 3 weeks followed by a 1-week treatment break

<b>Arm title</b>	Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab
------------------	---

Arm description:

Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

Arm type	Active comparator
Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Investigational medicinal product name	5-FU/LV or capecitabine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Per Investigator's discretion: 1600-2400 mg/m<sup>2</sup> administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m<sup>2</sup> administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m<sup>2</sup> twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

Number of subjects in period 2 <sup>[1]</sup>	Cohort 1: 5-FU/LV, cetuximab, vemurafenib	Cohort 1 Control: 5-FU/LV or capecitabine, bevacizumab	Cohort 2: 5-FU/LV or capecitabine, bevacizumab, atezolizumab
Started	40	20	297
Completed	6	2	66
Not completed	34	18	231
Physician decision	2	-	3
Non-Compliance	1	-	2
Consent withdrawn by subject	-	-	15
Study Ended by Sponsor	1	-	-
Adverse Event	-	-	1
Death	29	16	188
Not Treated	-	2	-
Reason Not Specified	-	-	7
Lost to follow-up	1	-	15

Number of subjects in period 2 <sup>[1]</sup>	Cohort 2 Control: 5-FU/LV or capecitabine, bevacizumab	Cohort 3: capecitabine, trastuzumab, pertuzumab	Cohort 3 Control: 5-FU/LV or capecitabine, bevacizumab
Started	148	3	2
Completed	21	0	1
Not completed	127	3	1
Physician decision	-	-	-
Non-Compliance	1	-	-
Consent withdrawn by subject	12	-	-
Study Ended by Sponsor	-	-	-
Adverse Event	1	-	-
Death	107	1	1
Not Treated	-	-	-
Reason Not Specified	2	1	-
Lost to follow-up	4	1	-

Number of subjects in period 2 <sup>[1]</sup>	Cohort 4: Cobimetinib, atezolizumab	Cohort 4 Control: 5-FU/LV or capecitabine, bevacizumab

Started	65	34
Completed	12	6
Not completed	53	28
Physician decision	1	3
Non-Compliance	-	-
Consent withdrawn by subject	2	3
Study Ended by Sponsor	-	-
Adverse Event	-	-
Death	46	19
Not Treated	-	-
Reason Not Specified	1	-
Lost to follow-up	3	3

#### Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Participants initially received study treatment during the Induction Treatment Phase. Next, participants within each cohort based on biomarker status were randomized to either an experimental arm or control arm per cohort in the Maintenance Treatment Phase. BRAFmut participants experiencing early disease progression during induction treatment had the option of proceeding immediately to receive second-line treatment in the separate Early Progression Period.

### Period 3

Period 3 title	Early Disease Progression
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

<b>Arm title</b>	Early Progressing BRAFmut Cohort
------------------	----------------------------------

#### Arm description:

BRAFmut participants experiencing early disease progression during induction treatment had the option of proceeding immediately to receive second-line treatment with 5-FU/LV, cetuximab and vemurafenib if their primary tumour was MSS, or with a fluoropyrimidine (5-FU/LV or capecitabine), bevacizumab, and atezolizumab if their primary tumour was MSI-H.

Arm type	Experimental
Investigational medicinal product name	Cetuximab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravascular use

#### Dosage and administration details:

500 mg/m<sup>2</sup> via IV infusion on Day 1 of every 2-week cycle

Investigational medicinal product name	Fluoropyrimidine (5-FU/LV or capecitabine)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

#### Dosage and administration details:

Per Investigator's discretion: 1600-2400 mg/m<sup>2</sup> administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m<sup>2</sup> administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m<sup>2</sup> twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen

fluoropyrimidine should be administered in accordance with local prescribing information.

Investigational medicinal product name	5-FU/LV
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1600-2400 mg/m<sup>2</sup> 5-FU via 46-hour IV infusion in combination with 400 mg/m<sup>2</sup> LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first.

Investigational medicinal product name	Vemurafenib
Investigational medicinal product code	
Other name	RO5185426
Pharmaceutical forms	Solution for infusion, Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

960 mg vemurafenib BID by mouth

Investigational medicinal product name	Bevacizumab
Investigational medicinal product code	
Other name	Avastin
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information

Investigational medicinal product name	Atezolizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg

Number of subjects in period 3 <sup>[2]</sup>	Early Progressing BRAFmut Cohort
Started	11
Completed	0
Not completed	11
Death	10
Lost to follow-up	1

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: BRAFmut participants experiencing early disease progression during induction treatment had the option of proceeding immediately to receive second-line treatment. These participants are presented in a separate arm in a separate period as they were not considered part of Maintenance Treatment.

## Baseline characteristics

### Reporting groups

Reporting group title	Cohort 1: Induction Phase (IP)
Reporting group description:	
Included participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.	
Reporting group title	Cohort 2 (IP)
Reporting group description:	
Included participants with BRAFwt. All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.	
Reporting group title	Cohort 3 (IP)
Reporting group description:	
Included participants with human epidermal growth factor receptor 2 positive (HER2+). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.	
Reporting group title	Cohort 4 (IP)
Reporting group description:	
Included participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.	

Reporting group values	Cohort 1: Induction Phase (IP)	Cohort 2 (IP)	Cohort 3 (IP)
Number of subjects	93	635	6
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	58	351	6
From 65-84 years	35	279	0
85 years and over	0	5	0
Age Continuous			
Units: years			
arithmetic mean	59.5	60.9	48.0
standard deviation	± 12.0	± 12.6	± 7.7

Sex: Female, Male			
Units:			
Female	49	247	4
Male	44	388	2

Reporting group values	Cohort 4 (IP)	Total	
Number of subjects	310	1044	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	199	614	
From 65-84 years	110	424	
85 years and over	1	6	
Age Continuous			
Units: years			
arithmetic mean	60.1		
standard deviation	± 10.3	-	
Sex: Female, Male			
Units:			
Female	123	423	
Male	187	621	



## End points

### End points reporting groups

Reporting group title	Cohort 1: Induction Phase (IP)
Reporting group description: Included participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.	
Reporting group title	Cohort 2 (IP)
Reporting group description: Included participants with BRAFwt. All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.	
Reporting group title	Cohort 3 (IP)
Reporting group description: Included participants with human epidermal growth factor receptor 2 positive (HER2+). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.	
Reporting group title	Cohort 4 (IP)
Reporting group description: Included participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFwt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.	
Reporting group title	Cohort 1: 5-FU/LV, cetuximab, vemurafenib
Reporting group description: Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) received 1600-2400 milligrams per square meter (mg/m <sup>2</sup> ) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m <sup>2</sup> LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m <sup>2</sup> cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.	
Reporting group title	Cohort 1 Control: 5-FU/LV or capecitabine, bevacizumab
Reporting group description: Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.	
Reporting group title	Cohort 2: 5-FU/LV or capecitabine, bevacizumab, atezolizumab
Reporting group description: Participants with BRAFwt received fluoropyrimidine (1600-2400 mg/m <sup>2</sup> 5-FU via 46-hour IV infusion in combination with 400 mg/m <sup>2</sup> LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m <sup>2</sup> twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.	
Reporting group title	Cohort 2 Control: 5-FU/LV or capecitabine, bevacizumab
Reporting group description: Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.	
Reporting group title	Cohort 3: capecitabine, trastuzumab, pertuzumab

#### Reporting group description:

Participants with human epidermal growth factor receptor 2 positive (HER2+) received 1000 mg/m<sup>2</sup> twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.

Reporting group title	Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab
-----------------------	---

#### Reporting group description:

Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

Reporting group title	Cohort 4: Cobimetinib,atezolizumab
-----------------------	------------------------------------

#### Reporting group description:

Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFWt); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) received 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.

Reporting group title	Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab
-----------------------	---

#### Reporting group description:

Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

Reporting group title	Early Progressing BRAFmut Cohort
-----------------------	----------------------------------

#### Reporting group description:

BRAFmut participants experiencing early disease progression during induction treatment had the option of proceeding immediately to receive second-line treatment with 5-FU/LV, cetuximab and vemurafenib if their primary tumour was MSS, or with a fluoropyrimidine (5-FU/LV or capecitabine), bevacizumab, and atezolizumab if their primary tumour was MSI-H.

### Primary: Progression-Free Survival

End point title	Progression-Free Survival
-----------------	---------------------------

#### End point description:

PFS is defined as the time from randomization to the first occurrence of disease progression according to RECIST v1.1, or death from any cause, whichever occurs first. Progressive disease (PD) for target lesion: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters on study (including baseline). In addition to the relative increase of 20%, the sum of diameters must also demonstrate an absolute increase of  $\geq 5$  mm. PD for non-target lesion: Unequivocal progression of existing non-target lesions. Analysis Population included participants in the Maintenance Treatment Phase (MTP) of the study, which included the experimental and control arms of Cohorts 1-4.

End point type	Primary
----------------	---------

#### End point timeframe:

From randomization until disease progression or death from any cause, up to 5 years

End point values	Cohort 1: 5-FU/LV,cetuximab,vemurafenib	Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab	Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	20	297	148
Units: months				
median (confidence interval 95%)	9.99 (7.72 to	11.60 (3.58 to	7.13 (6.14 to	7.36 (5.82 to

12.55)	15.67)	8.41)	8.94)
--------	--------	-------	-------

End point values	Cohort 3: capecitabine, trastuzumab, perituzumab	Cohort 3 Control: 5-FU/LV or capecitabine, bevacizumab	Cohort 4: Cobimetinib, atezolizumab	Cohort 4 Control: 5-FU/LV or capecitabine, bevacizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	2	65	34
Units: months				
median (confidence interval 95%)	4.44 (3.55 to 14.69)	4.04 (4.04 to 5.39)	3.75 (3.42 to 3.91)	7.79 (3.98 to 9.46)

## Statistical analyses

Statistical analysis title	MTP: Cohort 1 vs Cohort 1 Control
Comparison groups	Cohort 1: 5-FU/LV, cetuximab, vemurafenib v Cohort 1 Control: 5-FU/LV or capecitabine, bevacizumab
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.872
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.5
upper limit	1.82

Statistical analysis title	MTP: Cohort 4 vs Cohort 4 Control
Comparison groups	Cohort 4: Cobimetinib, atezolizumab v Cohort 4 Control: 5-FU/LV or capecitabine, bevacizumab
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.128
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.44
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	2.29

<b>Statistical analysis title</b>	MTP: Cohort 2 vs Cohort 2 Control
Comparison groups	Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab v Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab
Number of subjects included in analysis	445
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.666
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.95
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.18

## Secondary: Overall Survival

End point title	Overall Survival
End point description:	
OS is defined as the time from randomization into the MTP to time of death from any cause. Analysis Population included participants in the MTP of the study, which included the experimental and control arms of Cohorts 1-4.	
End point type	Secondary
End point timeframe:	
From randomization until death from any cause, up to 5 years	

<b>End point values</b>	Cohort 1: 5-FU/LV,cetuximab,vemurafenib	Early Progressing BRAFmut Cohort	Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	11	20	297
Units: months				
median (confidence interval 95%)	24.02 (16.07 to 34.00)	10.51 (4.83 to 19.78)	21.73 (7.92 to 37.19)	22.54 (20.04 to 26.87)

<b>End point values</b>	Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 3: capecitabine, trastuzumab, perituzumab	Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 4: Cobimetinib, atezolizumab
-------------------------	---	--	---	-------------------------------------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	148	0 <sup>[1]</sup>	0 <sup>[2]</sup>	65
Units: months				
median (confidence interval 95%)	22.24 (18.50 to 25.13)	( to )	( to )	22.60 (14.23 to 27.40)

Notes:

[1] - Both the Median and the 95% CI were not evaluable due to the low number of participants/events.

[2] - Both the Median and the 95% CI were not evaluable due to the low number of participants/events.

<b>End point values</b>	Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab			
Subject group type	Reporting group			
Number of subjects analysed	34			
Units: months				
median (confidence interval 95%)	25.17 (15.90 to 32.59)			

## Statistical analyses

<b>Statistical analysis title</b>	MTP: Cohort 1 vs Cohort 1 Control
Comparison groups	Cohort 1: 5-FU/LV, cetuximab, vemurafenib v Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.276
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.71
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.39
upper limit	1.32

<b>Statistical analysis title</b>	MTP: Cohort 4 vs Cohort 4 Control
Comparison groups	Cohort 4: Cobimetinib, atezolizumab v Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.415
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.25

Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	2.14

<b>Statistical analysis title</b>	MTP: Cohort 2 vs Cohort 2 Control
Comparison groups	Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab v Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab
Number of subjects included in analysis	445
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.076
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	0.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.64
upper limit	1.02

## Secondary: Percentage of Participants with Adverse Events

End point title	Percentage of Participants with Adverse Events
End point description:	
Safety population: all participants who received an intervention during the study.	
End point type	Secondary
End point timeframe:	
From baseline until end of study (up to 5 years)	

End point values	Cohort 1: Induction Phase (IP)	Cohort 1: 5- FU/LV,cetuxim ab,vemurafenib	Early Progressing BRAFmut Cohort	Cohort 2 (IP)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	93	40	11	632
Units: percentage of participants				
number (not applicable)	98.9	100	90.9	96.0

End point values	Cohort 1 Control: 5- FU/LV or capecitabin,	Cohort 3 (IP)	Cohort 2: 5- FU/LV or capecitabine,be vacizumab,	Cohort 4 (IP)
------------------	---	---------------	---	---------------

	bevacizumab		atezolizumab	
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	18	6	293	309
Units: percentage of participants				
number (not applicable)	94.4	100	95.6	97.4

End point values	Cohort 2 Control: 5- FU/LV or capecitabin, bevacizumab	Cohort 3: capecitabine,tr astuzumab,per tuzumab	Cohort 3 Control: 5- FU/LV or capecitabin, bevacizumab	Cohort 4: Cobimetinib,at ezolizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	143	3	2	64
Units: percentage of participants				
number (not applicable)	88.1	100	100	98.4

End point values	Cohort 4 Control: 5- FU/LV or capecitabin, bevacizumab			
Subject group type	Reporting group			
Number of subjects analysed	34			
Units: percentage of participants				
number (not applicable)	88.2			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Response

End point title	Overall Response
End point description:	
Calculated as the number of participants with a best overall response of CR or PR according to RECIST 1.1. CR: disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters, in the absence of CR. OR= CR + PR. Analysis Population included participants in the MTP of the study, which included the experimental and control arms of Cohorts 1-4.	
End point type	Secondary
End point timeframe:	
From randomization until disease progression, up to 5 years	

End point values	Cohort 1: 5-FU/LV, cetuximab, vemurafenib	Early Progressing BRAFmut Cohort	Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 2: 5-FU/LV or capecitabine, bevacizumab, atezolizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	11	20	297
Units: participants	20	2	5	49

End point values	Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 3: capecitabine, trastuzumab, pertuzumab	Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 4: Cobimetinib, atezolizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	148	3	2	65
Units: participants	22	1	0	7

End point values	Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab			
Subject group type	Reporting group			
Number of subjects analysed	34			
Units: participants	8			

## Statistical analyses

Statistical analysis title	MTP: Cohort 1 vs Cohort 1 Control
Comparison groups	Cohort 1: 5-FU/LV, cetuximab, vemurafenib v Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.064
Method	Chi-squared

Statistical analysis title	MTP: Cohort 4 vs Cohort 4 Control
Comparison groups	Cohort 4: Cobimetinib, atezolizumab v Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab



Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.093
Method	Chi-squared

<b>Statistical analysis title</b>	MTP: Cohort 2 vs Cohort 2 Control
Comparison groups	Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab v Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab
Number of subjects included in analysis	445
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.658
Method	Chi-squared

### Secondary: Disease Control Rate

End point title	Disease Control Rate
-----------------	----------------------

End point description:

DCR is defined as the percentage of participants with CR, PR, or stable disease (SD) at 16 weeks. Per RECIST v1.1, CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions. Analysis Population included participants in the MTP of the study, which included the experimental and control arms of Cohorts 1-4.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression, up to 5 years

<b>End point values</b>	Cohort 1: 5-FU/LV,cetuximab,vemurafenib	Early Progressing BRAFmut Cohort	Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 2: 5-FU/LV or capecitabine,bevacizumab,atezolizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	11	20	297
Units: participants	36	9	15	227

<b>End point values</b>	Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 3: capecitabine, trastuzumab, perituzumab	Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 4: Cobimetinib, atezolizumab
-------------------------	---	--	---	-------------------------------------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	148	3	2	65
Units: participants	111	1	0	44

<b>End point values</b>	Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab			
Subject group type	Reporting group			
Number of subjects analysed	34			
Units: participants	26			

### Statistical analyses

<b>Statistical analysis title</b>	MTP: Cohort 1 vs Cohort 1 Control
Comparison groups	Cohort 1: 5-FU/LV, cetuximab, vemurafenib v Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab
Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.125
Method	Chi-squared

<b>Statistical analysis title</b>	MTP: Cohort 4 vs Cohort 4 Control
Comparison groups	Cohort 4: Cobimetinib, atezolizumab v Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab
Number of subjects included in analysis	99
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.362
Method	Chi-squared

<b>Statistical analysis title</b>	MTP: Cohort 2 vs Cohort 2 Control
Comparison groups	Cohort 2: 5-FU/LV or capecitabine, bevacizumab, atezolizumab v Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab
Number of subjects included in analysis	445
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.739
Method	Chi-squared

## Secondary: Time to Treatment Response

End point title	Time to Treatment Response
-----------------	----------------------------

End point description:

Calculated as the time from randomization to the first Occurrence of a documented Objective Response (CR or PR) determined according to RECIST 1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Analysis Population included participants in the MTP of the study, which included the experimental and control arms of Cohorts 1-4.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until disease progression or death from any cause, up to 5 years

End point values	Cohort 1: 5-FU/LV, cetuximab, vemurafenib	Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 2: 5-FU/LV or capecitabine, bevacizumab, atezolizumab	Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	20	297	148
Units: months				
median (full range (min-max))	3.943 (1.18 to 29.70)	5.552 (1.38 to 8.02)	5.224 (1.22 to 26.74)	4.616 (1.25 to 19.91)

End point values	Cohort 3: capecitabine, trastuzumab, pertuzumab	Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 4: Cobimetinib, atezolizumab	Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	2	0 <sup>[3]</sup>	0 <sup>[4]</sup>
Units: months				
median (full range (min-max))	5.490 (5.490 to 5.490)	0 (0 to 0)	( to )	( to )

Notes:

[3] - Target number of patients not enrolled and the target number of PFS events could not be reached

[4] - Target number of patients not enrolled and the target number of PFS events could not be reached

## Statistical analyses

No statistical analyses for this end point

## Secondary: Duration of Response

End point title	Duration of Response
-----------------	----------------------

End point description:

Defined as the time from the first assessment of CR or PR until disease progression or death from any cause, whichever occurs first. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. Analysis Population included participants in the MTP of the study, which included the

experimental and control arms of Cohorts 1-4.

End point type	Secondary
End point timeframe:	
From first objective response until disease progression or death from any cause, up to 5 years	

<b>End point values</b>	Cohort 1: 5-FU/LV, cetuximab, vemurafenib	Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 2: 5-FU/LV or capecitabine, bevacizumab, atezolizumab	Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	20	297	148
Units: months				
median (confidence interval 95%)	11.50 (7.66 to 21.49)	8.74 (5.36 to 19.02)	9.30 (5.55 to 11.30)	7.59 (6.93 to 13.90)

<b>End point values</b>	Cohort 3: capecitabine, trastuzumab, pertuzumab	Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 4: Cobimetinib, atezolizumab	Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	2	0 <sup>[5]</sup>	0 <sup>[6]</sup>
Units: months				
median (confidence interval 95%)	9.205 (9.205 to 9.205)	0 (0 to 0)	( to )	( to )

Notes:

[5] - Target number of patients not enrolled and the target number of PFS events could not be reached

[6] - Target number of patients not enrolled and the target number of PFS events could not be reached

### Statistical analyses

<b>Statistical analysis title</b>	MTP: Cohort 2 vs Cohort 2 Control
Comparison groups	Cohort 2: 5-FU/LV or capecitabine, bevacizumab, atezolizumab v Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab
Number of subjects included in analysis	445
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.495
Method	Logrank

<b>Statistical analysis title</b>	MTP: Cohort 1 vs Cohort 1 Control
Comparison groups	Cohort 1: 5-FU/LV, cetuximab, vemurafenib v Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab

Number of subjects included in analysis	60
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.421
Method	Logrank

## Secondary: Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score

End point title	Percentage of Participants With Improvement and/or Stayed the Same on the Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score
-----------------	---

End point description:

Analysis Population included participants in the MTP of the study, which included the experimental and control arms of Cohorts 1-4.

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline until end of study (up to 5 years)

End point values	Cohort 1: 5-FU/LV, cetuximab, vemurafenib	Cohort 1 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 2: 5-FU/LV or capecitabine, bevacizumab, atezolizumab	Cohort 2 Control: 5-FU/LV or capecitabin, bevacizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	40	20	297	148
Units: percentage of participants				
number (not applicable)				
Improved	10.0	5.0	10.4	5.4
Improved or stayed the same	75.0	85.0	76.7	82.5

End point values	Cohort 3: capecitabine, trastuzumab, pertuzumab	Cohort 3 Control: 5-FU/LV or capecitabin, bevacizumab	Cohort 4: Cobimetinib, atezolizumab	Cohort 4 Control: 5-FU/LV or capecitabin, bevacizumab
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	2	65	34
Units: percentage of participants				
number (not applicable)				
Improved	0	0	7.7	5.9
Improved or stayed the same	100	100	63.1	79.4

## Statistical analyses



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From baseline until end of study (up to 5 years)

Adverse event reporting additional description:

The safety population included all participants who received an intervention during the study.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.1
--------------------	------

### Reporting groups

Reporting group title	Cohort 1: Induction Phase (IP)
-----------------------	--------------------------------

Reporting group description:

Included participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFmut)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.

Reporting group title	Cohort 1 Control (MP): 5-FU/LV or capecitabine, bevacizumab
-----------------------	---

Reporting group description:

Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

Reporting group title	Cohort 2 (IP)
-----------------------	---------------

Reporting group description:

Included participants with BRAFwt. All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/ leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.

Reporting group title	Cohort 2 (MP):5-FU/LV or capecitabine,bevacizumab,atezolizumab
-----------------------	--

Reporting group description:

Participants with BRAFwt received fluoropyrimidine (1600-2400 mg/m<sup>2</sup> 5-FU via 46-hour IV infusion in combination with 400 mg/m<sup>2</sup> LV via 2-hour infusion on Day 1 of every 2-week cycle or 1000 mg/m<sup>2</sup> twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break) with 5 milligrams per kilogram (mg/kg) bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle and 800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle.

Reporting group title	Cohort 2 Control (MP): 5-FU/LV or capecitabine, bevacizumab
-----------------------	---

Reporting group description:

Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

Reporting group title	Early Progressing BRAFmut Cohort
-----------------------	----------------------------------

Reporting group description:

BRAFmut participants experiencing early disease progression during induction treatment had the option of proceeding immediately to receive second-line treatment with 5-FU/LV, cetuximab and vemurafenib if their primary tumor was MSS, or with a fluoropyrimidine (5-FU/LV or capecitabine), bevacizumab, and atezolizumab if their primary tumor was MSI-H. This cohort was followed during the study, but was not part of the Maintenance Phase study objectives.

Reporting group title	Cohort 3 (MP): capecitabine,trastuzumab,pertuzumab
-----------------------	--

Reporting group description:

Participants with human epidermal growth factor receptor 2 positive (HER2+) received 1000 mg/m<sup>2</sup> twice-daily capecitabine BID by mouth on Days 1-14 every 2 weeks followed by a 1-week break with trastuzumab by IV infusion on Day 1 of every 3-week treatment cycle at an initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses, and pertuzumab by IV infusion on Day 1 of each 3-

week treatment cycle at an initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses.

Reporting group title	Cohort 3 Control (MP): 5-FU/LV or capecitabin, bevacizumab
-----------------------	--

Reporting group description:

Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

Reporting group title	Cohort 4 (IP)
-----------------------	---------------

Reporting group description:

Included participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFWT); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.

Reporting group title	Cohort 4 (MP): Cobimetinib,atezolizumab
-----------------------	---

Reporting group description:

Participants with HER2-/high microsatellite instability (MSI-H); HER2-/MSS/v-raf murine sarcoma viral oncogene homolog B1 wild type (BRAFWT); HER2-/MSS/BRAFmut/rat sarcoma mutation positive (RASmut) received 60 mg cobimetinib orally for 3 weeks followed by a 1-week treatment break and atezolizumab at a fixed dose of 840 mg via 60-minute IV infusion on Day 1 of every 2-week cycle.

Reporting group title	Cohort 4 Control (MP): 5-FU/LV or capecitabin, bevacizumab
-----------------------	--

Reporting group description:

Per Investigator discretion, participants received fluoropyrimidine (5-FU/LV or capecitabine) at a dose and schedule per the Investigator's discretion in accordance with locally approved prescribing information and 5 mg/kg bevacizumab via 1-30 minute IV on Day 1 of every 2-week cycle.

Reporting group title	Cohort 1 (Maintenance Phase[MP]):5-FU/LV,cetuximab,vemurafenib
-----------------------	--

Reporting group description:

Participants with v-raf murine sarcoma viral oncogene homolog B1 mutation positive (BRAFWT)/human epidermal growth factor receptor 2 negative (HER2-)/microsatellite stable (MSS)/rat sarcoma wild type (RASwt) received 1600-2400 milligrams per square meter (mg/m<sup>2</sup>) 5-FU via 46-hour intravenous (IV) infusion in combination with 400 mg/m<sup>2</sup> LV via 2-hour infusion on Day 1 of every 2-week cycle with 500 mg/m<sup>2</sup> cetuximab via infusion on Day 1 of every 2-week cycle and 960 milligrams (mg) vemurafenib twice daily (BID) by mouth.

Reporting group title	Cohort 3 (IP)
-----------------------	---------------

Reporting group description:

Included participants with human epidermal growth factor receptor 2 positive (HER2+). All study participants received either eight 2-week cycles of 5-fluorouracil (5-FU)/leucovorin calcium (LV) and oxaliplatin (FOLFOX) in combination with bevacizumab, or six 2-week cycles of FOLFOX in combination with bevacizumab, followed by two 2-week cycles of 5-FU/LV with bevacizumab during Induction Treatment.

<b>Serious adverse events</b>	Cohort 1: Induction Phase (IP)	Cohort 1 Control (MP): 5-FU/LV or capecitabin, bevacizumab	Cohort 2 (IP)
Total subjects affected by serious adverse events			
subjects affected / exposed	44 / 93 (47.31%)	5 / 18 (27.78%)	232 / 632 (36.71%)
number of deaths (all causes)	25	16	111
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			



subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Second primary malignancy			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour perforation			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine tumour			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Arterial thrombosis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	1 / 1	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	6 / 632 (0.95%)
occurrences causally related to treatment / all	0 / 0	0 / 0	6 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dry gangrene			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Embolism venous			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subclavian vein thrombosis			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery occlusion			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Ureteral stent removal			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	1 / 1	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site dehiscence			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General physical health deterioration			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	6 / 632 (0.95%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Hyperthermia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site thrombosis			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion site extravasation			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	14 / 632 (2.22%)
occurrences causally related to treatment / all	0 / 1	0 / 0	4 / 15
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	2 / 2
Euthanasia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Influenza like illness			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related hypersensitivity reaction			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	7 / 632 (1.11%)
occurrences causally related to treatment / all	1 / 1	0 / 0	6 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Hypoventilation			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary thrombosis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Psychiatric disorders			
Disorientation			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Blood triglycerides increased			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipase increased			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	1 / 1	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amylase increased			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic enzyme increased			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza A virus test positive			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Anastomotic ulcer			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Femur fracture			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma site haemorrhage			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheal haemorrhage			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incision site impaired healing			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative thoracic procedure complication			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Coronary artery disease			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Restrictive cardiomyopathy			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute coronary syndrome			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial thrombosis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral motor neuropathy			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reversible cerebral vasoconstriction syndrome			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiplegia			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	10 / 632 (1.58%)
occurrences causally related to treatment / all	0 / 0	0 / 0	13 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	12 / 632 (1.90%)
occurrences causally related to treatment / all	2 / 2	0 / 0	11 / 13
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic haematoma			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			

Vertigo			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Chorioretinopathy			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Choroidal effusion			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal haemorrhage			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	4 / 632 (0.63%)
occurrences causally related to treatment / all	0 / 2	0 / 0	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	7 / 632 (1.11%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Diarrhoea			
subjects affected / exposed	5 / 93 (5.38%)	1 / 18 (5.56%)	13 / 632 (2.06%)
occurrences causally related to treatment / all	4 / 5	1 / 1	9 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal obstruction			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	2 / 93 (2.15%)	1 / 18 (5.56%)	10 / 632 (1.58%)
occurrences causally related to treatment / all	0 / 2	0 / 1	3 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	4 / 632 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	5 / 632 (0.79%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			



subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	1 / 1	0 / 0	3 / 3
deaths causally related to treatment / all	1 / 1	0 / 0	1 / 1
Large intestinal stenosis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	5 / 632 (0.79%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	0 / 1	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctalgia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	4 / 632 (0.63%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	10 / 632 (1.58%)
occurrences causally related to treatment / all	4 / 4	0 / 0	6 / 10
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal necrosis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colonic fistula			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal perforation			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumatosis intestinalis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal haemorrhage			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis mesenteric vessel			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal perforation			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal perforation			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			

subjects affected / exposed	2 / 93 (2.15%)	1 / 18 (5.56%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Hepatocellular injury			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatorenal failure			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Hepatotoxicity			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema multiforme			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraneoplastic dermatomyositis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	5 / 632 (0.79%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bone pain			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	2 / 93 (2.15%)	1 / 18 (5.56%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	1 / 2	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			

subjects affected / exposed	2 / 93 (2.15%)	1 / 18 (5.56%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gingivitis			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis clostridial			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic infection			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Labyrinthitis			



subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	8 / 632 (1.27%)
occurrences causally related to treatment / all	0 / 1	0 / 0	4 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	6 / 632 (0.95%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Staphylococcal infection			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	8 / 632 (1.27%)
occurrences causally related to treatment / all	0 / 1	0 / 0	2 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular device infection			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	6 / 632 (0.95%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural sepsis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fournier's gangrene			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious pleural effusion			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary infection			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic abscess			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perirectal abscess			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomembranous colitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal cyst			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	3 / 93 (3.23%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences causally related to treatment / all	2 / 5	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			

subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lactic acidosis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Cohort 2 (MP):5-FU/LV or capecitabine,bevacizumab,atezolizumab	Cohort 2 Control (MP): 5-FU/LV or capecitabin, bevacizumab	Early Progressing BRAFmut Cohort
Total subjects affected by serious adverse events			
subjects affected / exposed	76 / 293 (25.94%)	20 / 143 (13.99%)	3 / 11 (27.27%)
number of deaths (all causes)	185	102	10
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Second primary malignancy			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour perforation			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine tumour			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Arterial thrombosis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	3 / 293 (1.02%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			

subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dry gangrene			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism venous			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subclavian vein thrombosis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery occlusion			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Ureteral stent removal			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site dehiscence			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site thrombosis			



subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion site extravasation			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	6 / 293 (2.05%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Euthanasia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related hypersensitivity reaction			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pulmonary embolism			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoventilation			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary thrombosis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Disorientation			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood triglycerides increased			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipase increased			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Amylase increased			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic enzyme increased			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza A virus test positive			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Anastomotic ulcer			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Spinal fracture			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma site haemorrhage			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheal haemorrhage			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incision site impaired healing			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative thoracic procedure complication			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Coronary artery disease			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Restrictive cardiomyopathy			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute coronary syndrome			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			



subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial thrombosis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral motor neuropathy			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reversible cerebral vasoconstriction syndrome			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiplegia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			

subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic haematoma			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Chorioretinopathy			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Choroidal effusion			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal haemorrhage			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	3 / 293 (1.02%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	5 / 293 (1.71%)	2 / 143 (1.40%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	3 / 5	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal obstruction			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Large intestinal stenosis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			

subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctalgia			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			

subjects affected / exposed	4 / 293 (1.37%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal necrosis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colonic fistula			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal perforation			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumatosis intestinalis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal haemorrhage			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis mesenteric vessel			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal perforation			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal perforation			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Hepatocellular injury			



subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatorenal failure			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Hepatotoxicity			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema multiforme			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palmar-plantar erythrodysaesthesia syndrome			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraneoplastic dermatomyositis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

Hypothyroidism			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Abdominal infection			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			

subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gingivitis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis clostridial			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic infection			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Labyrinthitis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			

subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	3 / 293 (1.02%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular device infection			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural sepsis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fournier's gangrene			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious pleural effusion			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary infection			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic abscess			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perirectal abscess			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomembranous colitis			



subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal cyst			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lactic acidosis			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Cohort 3 (MP): capecitabine,trastuzumab,pertuzumab	Cohort 3 Control (MP): 5-FU/LV or capecitabin, bevacizumab	Cohort 4 (IP)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	93 / 309 (30.10%)
number of deaths (all causes)	1	1	82
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Second primary malignancy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour perforation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine tumour			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Arterial thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dry gangrene			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism venous			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subclavian vein thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery occlusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Ureteral stent removal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gait disturbance			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site dehiscence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion site extravasation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	8 / 309 (2.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Euthanasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related hypersensitivity reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			

Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Pulmonary oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoventilation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Disorientation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			



Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood triglycerides increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amylase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic enzyme increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza A virus test positive			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Anastomotic ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma site haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incision site impaired healing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative thoracic procedure complication			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Myocardial ischaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Restrictive cardiomyopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute coronary syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral motor neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reversible cerebral vasoconstriction syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiplegia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	4 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Chorioretinopathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Choroidal effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	6 / 309 (1.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Colitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	4 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Intestinal obstruction			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated enterocolitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal stenosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctalgia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal necrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colonic fistula			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal perforation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumatosis intestinalis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis mesenteric vessel			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Small intestinal perforation			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal perforation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatorenal failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatotoxicity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema multiforme			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraneoplastic dermatomyositis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	8 / 309 (2.59%)
occurrences causally related to treatment / all	0 / 0	0 / 0	6 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2

Nephrolithiasis	subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure	subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
	deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Renal colic	subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria	subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction	subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders				
Hypothyroidism	subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders				
Arthralgia	subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain	subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			



subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Device related infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gingivitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis clostridial			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Labyrinthitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pyelonephritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Septic shock			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Vascular device infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural sepsis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fournier's gangrene			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Encephalitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Infectious pleural effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic abscess			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perirectal abscess			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomembranous colitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal cyst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lactic acidosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Cohort 4 (MP): Cobimetinib,atezolizumab	Cohort 4 Control (MP): 5-FU/LV or capecitabin, bevacizumab	Cohort 1 (Maintenance Phase[MP]):5-FU/LV,cetuximab,ve murafenib
Total subjects affected by serious adverse events			
subjects affected / exposed	26 / 64 (40.63%)	3 / 34 (8.82%)	15 / 40 (37.50%)
number of deaths (all causes)	46	19	29
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Second primary malignancy			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour perforation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuroendocrine tumour			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour haemorrhage			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Arterial thrombosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Superior vena cava syndrome			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dry gangrene			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism venous			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subclavian vein thrombosis			



subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery occlusion			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Surgical and medical procedures			
Ureteral stent removal			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gait disturbance			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site dehiscence			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General physical health deterioration			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperthermia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Implant site thrombosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion site extravasation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Euthanasia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mucosal inflammation			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypersensitivity			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related hypersensitivity reaction			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Organising pneumonia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Pulmonary oedema			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoventilation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary thrombosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Disorientation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Confusional state			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	3 / 64 (4.69%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	3 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Blood triglycerides increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipase increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutrophil count decreased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amylase increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic enzyme increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza A virus test positive			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Anastomotic ulcer			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Femur fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incisional hernia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stoma site haemorrhage			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tracheal haemorrhage			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral neck fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal anastomotic leak			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incision site impaired healing			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative thoracic procedure complication			



subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Restrictive cardiomyopathy			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute coronary syndrome			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial thrombosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericarditis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral motor neuropathy			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reversible cerebral vasoconstriction syndrome			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiplegia			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic haematoma			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			

Vertigo			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Chorioretinopathy			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Choroidal effusion			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal haemorrhage			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 64 (1.56%)	1 / 34 (2.94%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Diarrhoea			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	3 / 3	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Faecaloma			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal obstruction			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune-mediated enterocolitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal stenosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal obstruction			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proctalgia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stomatitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subileus			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal fistula			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal necrosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colonic fistula			



subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal perforation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumatosis intestinalis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestinal haemorrhage			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoidal haemorrhage			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis mesenteric vessel			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal perforation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal perforation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholestasis			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatocellular injury			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatorenal failure			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatotoxicity			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash			

subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urticaria			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema multiforme			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paraneoplastic dermatomyositis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal colic			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bone pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fistula			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal abscess			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall abscess			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis infective			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gingivitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis clostridial			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Labyrinthitis			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine infection			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal abscess			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Vascular device infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural sepsis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial sepsis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site infection			



subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fournier's gangrene			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infectious pleural effusion			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic abscess			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Perirectal abscess			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomembranous colitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pilonidal cyst			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic ketoacidosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypokalaemia</b>			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hyponatraemia</b>			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Lactic acidosis</b>			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Cohort 3 (IP)		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 6 (16.67%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events			
<b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b>			
<b>Cancer pain</b>			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Second primary malignancy</b>			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
<b>Tumour perforation</b>			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Leiomyosarcoma			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Neuroendocrine tumour			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tumour haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Arterial thrombosis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Deep vein thrombosis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertension			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Superior vena cava syndrome			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombosis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dry gangrene			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Embolism			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Embolism venous			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subclavian vein thrombosis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral artery occlusion			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Surgical and medical procedures			
Ureteral stent removal			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			

Asthenia				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chest pain				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gait disturbance				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fatigue				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Implant site dehiscence				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
General physical health deterioration				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hyperthermia				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Implant site thrombosis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infusion site extravasation				

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Death			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Euthanasia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mucosal inflammation			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multiple organ dysfunction syndrome			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypersensitivity			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infusion related hypersensitivity reaction			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Interstitial lung disease			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epistaxis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		



Pneumothorax				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory failure				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute respiratory distress syndrome				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Organising pneumonia				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary oedema				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypoventilation				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary thrombosis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory distress				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Psychiatric disorders				

Disorientation				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Confusional state				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Investigations				
Blood creatine phosphokinase increased				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood lactate dehydrogenase increased				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood triglycerides increased				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lipase increased				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neutrophil count decreased				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Amylase increased				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Hepatic enzyme increased subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Influenza A virus test positive subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Platelet count decreased subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Anastomotic ulcer subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femur fracture subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Incisional hernia subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post procedural haemorrhage subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal fracture subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Rib fracture				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Stoma site haemorrhage				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tendon rupture				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tibia fracture				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tracheal haemorrhage				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pelvic fracture				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fall				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Femoral neck fracture				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal anastomotic leak				

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Incision site impaired healing			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infusion related reaction			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subdural haematoma			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Postoperative thoracic procedure complication			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coronary artery disease			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiogenic shock			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial ischaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pericardial effusion			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Restrictive cardiomyopathy			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Supraventricular tachycardia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute coronary syndrome			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Angina pectoris			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac tamponade			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrial thrombosis			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute myocardial infarction			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pericarditis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhage intracranial			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoaesthesia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Peripheral motor neuropathy			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Presyncope			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Seizure			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reversible cerebral vasoconstriction syndrome			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hemiplegia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Somnolence			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Febrile neutropenia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anaemia			



subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukopenia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancytopenia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Splenic haematoma			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Chorioretinopathy			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Choroidal effusion			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			

Abdominal pain				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abdominal pain upper				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colitis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Constipation				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Faecaloma				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal obstruction				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrooesophageal reflux disease				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ileus				

subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intestinal perforation				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intestinal obstruction				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Immune-mediated enterocolitis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large intestine perforation				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large intestinal stenosis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large intestinal obstruction				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower gastrointestinal haemorrhage				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nausea				

subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal haemorrhage				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Proctalgia				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophagitis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Small intestinal obstruction				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Stomatitis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Subileus				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vomiting				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper gastrointestinal haemorrhage				

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal fistula			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal necrosis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colonic fistula			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal perforation			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumatosis intestinalis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Large intestinal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemorrhoidal haemorrhage			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombosis mesenteric vessel			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small intestinal perforation			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rectal perforation			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholestasis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic failure			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatocellular injury			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatorenal failure			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatotoxicity			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Rash maculo-papular			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rash			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urticaria			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Erythema multiforme			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Paraneoplastic dermatomyositis			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nephrolithiasis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal colic			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract obstruction			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue			



disorders				
Arthralgia				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Back pain				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Muscular weakness				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteonecrosis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bone pain				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fistula				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
Abdominal abscess				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abdominal infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Abdominal wall abscess				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anal abscess				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arthritis infective				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchitis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Device related infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Erysipelas				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gingivitis				

subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis clostridial				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatic infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Labyrinthitis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lower respiratory tract infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large intestine infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis				

subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal abscess				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory tract infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Septic shock				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Staphylococcal infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urosepsis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection				

subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vascular device infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural sepsis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bacterial sepsis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Catheter site infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis norovirus				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fournier's gangrene				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Encephalitis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infectious pleural effusion				

subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatobiliary infection				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Influenza				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pelvic abscess				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intervertebral discitis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Perirectal abscess				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peritonitis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pseudomembranous colitis				
subjects affected / exposed	0 / 6 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pilonidal cyst				

subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Diabetic ketoacidosis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lactic acidosis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Cohort 1: Induction Phase (IP)	Cohort 1 Control (MP): 5-FU/LV or capecitabin, bevacizumab	Cohort 2 (IP)
Total subjects affected by non-serious adverse events subjects affected / exposed	91 / 93 (97.85%)	17 / 18 (94.44%)	608 / 632 (96.20%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Melanocytic naevus subjects affected / exposed occurrences (all)	1 / 93 (1.08%) 1	0 / 18 (0.00%) 0	1 / 632 (0.16%) 1
Cancer pain subjects affected / exposed occurrences (all)	0 / 93 (0.00%) 0	0 / 18 (0.00%) 0	5 / 632 (0.79%) 5
Tumour associated fever subjects affected / exposed occurrences (all)	0 / 93 (0.00%) 0	0 / 18 (0.00%) 0	0 / 632 (0.00%) 0
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	16 / 93 (17.20%) 21	1 / 18 (5.56%) 1	170 / 632 (26.90%) 244
Hypotension subjects affected / exposed occurrences (all)	8 / 93 (8.60%) 8	0 / 18 (0.00%) 0	10 / 632 (1.58%) 10
Phlebitis subjects affected / exposed occurrences (all)	2 / 93 (2.15%) 3	0 / 18 (0.00%) 0	6 / 632 (0.95%) 6
General disorders and administration site conditions Face oedema subjects affected / exposed occurrences (all)	0 / 93 (0.00%) 0	0 / 18 (0.00%) 0	3 / 632 (0.47%) 5
Asthenia subjects affected / exposed occurrences (all)	20 / 93 (21.51%) 32	1 / 18 (5.56%) 2	115 / 632 (18.20%) 214
Fatigue			



subjects affected / exposed	31 / 93 (33.33%)	2 / 18 (11.11%)	247 / 632 (39.08%)
occurrences (all)	50	2	403
Influenza like illness			
subjects affected / exposed	5 / 93 (5.38%)	0 / 18 (0.00%)	21 / 632 (3.32%)
occurrences (all)	5	0	22
Mucosal inflammation			
subjects affected / exposed	16 / 93 (17.20%)	2 / 18 (11.11%)	69 / 632 (10.92%)
occurrences (all)	22	4	90
Pain			
subjects affected / exposed	3 / 93 (3.23%)	0 / 18 (0.00%)	16 / 632 (2.53%)
occurrences (all)	3	0	16
Pyrexia			
subjects affected / exposed	19 / 93 (20.43%)	1 / 18 (5.56%)	93 / 632 (14.72%)
occurrences (all)	20	1	144
Oedema peripheral			
subjects affected / exposed	9 / 93 (9.68%)	0 / 18 (0.00%)	25 / 632 (3.96%)
occurrences (all)	13	0	25
Catheter site pain			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences (all)	1	0	4
General physical health deterioration			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	8 / 632 (1.27%)
occurrences (all)	2	0	8
Malaise			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	8 / 632 (1.27%)
occurrences (all)	2	0	9
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	3 / 93 (3.23%)	0 / 18 (0.00%)	15 / 632 (2.37%)
occurrences (all)	3	0	15
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	3 / 632 (0.47%)
occurrences (all)	1	1	3
Cough			

subjects affected / exposed	11 / 93 (11.83%)	3 / 18 (16.67%)	77 / 632 (12.18%)
occurrences (all)	12	3	95
Dysphonia			
subjects affected / exposed	6 / 93 (6.45%)	1 / 18 (5.56%)	47 / 632 (7.44%)
occurrences (all)	7	1	61
Dyspnoea			
subjects affected / exposed	8 / 93 (8.60%)	2 / 18 (11.11%)	47 / 632 (7.44%)
occurrences (all)	11	2	51
Pulmonary embolism			
subjects affected / exposed	6 / 93 (6.45%)	1 / 18 (5.56%)	19 / 632 (3.01%)
occurrences (all)	7	1	19
Nasal ulcer			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	0 / 632 (0.00%)
occurrences (all)	1	1	0
Nasal dryness			
subjects affected / exposed	2 / 93 (2.15%)	1 / 18 (5.56%)	5 / 632 (0.79%)
occurrences (all)	3	1	5
Epistaxis			
subjects affected / exposed	18 / 93 (19.35%)	1 / 18 (5.56%)	121 / 632 (19.15%)
occurrences (all)	24	1	157
Hiccups			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	20 / 632 (3.16%)
occurrences (all)	1	1	26
Oropharyngeal pain			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	20 / 632 (3.16%)
occurrences (all)	2	0	27
Psychiatric disorders			
Anxiety			
subjects affected / exposed	6 / 93 (6.45%)	1 / 18 (5.56%)	19 / 632 (3.01%)
occurrences (all)	7	1	19
Insomnia			
subjects affected / exposed	14 / 93 (15.05%)	1 / 18 (5.56%)	38 / 632 (6.01%)
occurrences (all)	14	1	40
Depression			
subjects affected / exposed	3 / 93 (3.23%)	0 / 18 (0.00%)	12 / 632 (1.90%)
occurrences (all)	3	0	13

Product issues			
Device occlusion			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences (all)	3	0	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	5 / 93 (5.38%)	0 / 18 (0.00%)	34 / 632 (5.38%)
occurrences (all)	7	0	52
Amylase increased			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences (all)	2	0	2
Aspartate aminotransferase increased			
subjects affected / exposed	6 / 93 (6.45%)	1 / 18 (5.56%)	35 / 632 (5.54%)
occurrences (all)	9	1	45
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	19 / 632 (3.01%)
occurrences (all)	3	0	20
Ejection fraction decreased			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences (all)	0	0	1
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	5 / 93 (5.38%)	0 / 18 (0.00%)	13 / 632 (2.06%)
occurrences (all)	8	0	19
Blood bilirubin increased			
subjects affected / exposed	4 / 93 (4.30%)	1 / 18 (5.56%)	18 / 632 (2.85%)
occurrences (all)	6	1	24
Lipase increased			
subjects affected / exposed	4 / 93 (4.30%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences (all)	4	0	3
Neutrophil count decreased			
subjects affected / exposed	13 / 93 (13.98%)	0 / 18 (0.00%)	67 / 632 (10.60%)
occurrences (all)	17	0	108
Platelet count decreased			

subjects affected / exposed	4 / 93 (4.30%)	0 / 18 (0.00%)	40 / 632 (6.33%)
occurrences (all)	7	0	74
Weight increased			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	10 / 632 (1.58%)
occurrences (all)	1	0	11
Weight decreased			
subjects affected / exposed	11 / 93 (11.83%)	2 / 18 (11.11%)	64 / 632 (10.13%)
occurrences (all)	12	2	69
Cardiac murmur			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	1	0	0
Blood potassium decreased			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences (all)	1	0	1
C-reactive protein increased			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	7 / 632 (1.11%)
occurrences (all)	1	0	8
Body temperature increased			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	1	0	0
White blood cell count decreased			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	16 / 632 (2.53%)
occurrences (all)	2	0	23
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	7 / 632 (1.11%)
occurrences (all)	1	0	8
Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	5 / 93 (5.38%)	0 / 18 (0.00%)	17 / 632 (2.69%)
occurrences (all)	6	0	28
Lumbar vertebral fracture			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences (all)	1	0	1
Sunburn			

subjects affected / exposed	4 / 93 (4.30%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences (all)	4	0	1
Gastrointestinal stoma complication			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences (all)	1	0	3
Stoma site pain			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences (all)	0	0	4
Wound dehiscence			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	4 / 632 (0.63%)
occurrences (all)	1	0	4
Nervous system disorders			
Dizziness			
subjects affected / exposed	6 / 93 (6.45%)	1 / 18 (5.56%)	29 / 632 (4.59%)
occurrences (all)	11	2	35
Dysgeusia			
subjects affected / exposed	9 / 93 (9.68%)	0 / 18 (0.00%)	59 / 632 (9.34%)
occurrences (all)	11	0	71
Headache			
subjects affected / exposed	7 / 93 (7.53%)	0 / 18 (0.00%)	73 / 632 (11.55%)
occurrences (all)	10	0	179
Peripheral motor neuropathy			
subjects affected / exposed	3 / 93 (3.23%)	0 / 18 (0.00%)	10 / 632 (1.58%)
occurrences (all)	5	0	11
Neurotoxicity			
subjects affected / exposed	9 / 93 (9.68%)	0 / 18 (0.00%)	22 / 632 (3.48%)
occurrences (all)	15	0	31
Paraesthesia			
subjects affected / exposed	20 / 93 (21.51%)	0 / 18 (0.00%)	93 / 632 (14.72%)
occurrences (all)	29	0	125
Neuropathy peripheral			
subjects affected / exposed	10 / 93 (10.75%)	0 / 18 (0.00%)	103 / 632 (16.30%)
occurrences (all)	11	0	145
Peripheral sensory neuropathy			
subjects affected / exposed	26 / 93 (27.96%)	1 / 18 (5.56%)	222 / 632 (35.13%)
occurrences (all)	33	1	357

Polyneuropathy subjects affected / exposed occurrences (all)	3 / 93 (3.23%) 3	1 / 18 (5.56%) 1	26 / 632 (4.11%) 35
Restless legs syndrome subjects affected / exposed occurrences (all)	3 / 93 (3.23%) 3	1 / 18 (5.56%) 1	1 / 632 (0.16%) 1
Somnolence subjects affected / exposed occurrences (all)	3 / 93 (3.23%) 3	0 / 18 (0.00%) 0	5 / 632 (0.79%) 7
Taste disorder subjects affected / exposed occurrences (all)	4 / 93 (4.30%) 4	0 / 18 (0.00%) 0	13 / 632 (2.06%) 13
Sensory loss subjects affected / exposed occurrences (all)	1 / 93 (1.08%) 2	1 / 18 (5.56%) 1	0 / 632 (0.00%) 0
Ageusia subjects affected / exposed occurrences (all)	1 / 93 (1.08%) 1	0 / 18 (0.00%) 0	2 / 632 (0.32%) 2
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	20 / 93 (21.51%) 28	1 / 18 (5.56%) 2	87 / 632 (13.77%) 114
Leukopenia subjects affected / exposed occurrences (all)	5 / 93 (5.38%) 6	0 / 18 (0.00%) 0	40 / 632 (6.33%) 57
Neutropenia subjects affected / exposed occurrences (all)	22 / 93 (23.66%) 31	1 / 18 (5.56%) 1	133 / 632 (21.04%) 220
Thrombocytopenia subjects affected / exposed occurrences (all)	4 / 93 (4.30%) 5	0 / 18 (0.00%) 0	45 / 632 (7.12%) 67
Ear and labyrinth disorders			
Auditory meatus external erosion subjects affected / exposed occurrences (all)	1 / 93 (1.08%) 1	0 / 18 (0.00%) 0	0 / 632 (0.00%) 0
Eye disorders			

Cataract			
subjects affected / exposed	4 / 93 (4.30%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences (all)	5	0	4
Conjunctival haemorrhage			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	2 / 632 (0.32%)
occurrences (all)	1	1	2
Lacrimation increased			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	14 / 632 (2.22%)
occurrences (all)	1	1	17
Periorbital oedema			
subjects affected / exposed	3 / 93 (3.23%)	1 / 18 (5.56%)	2 / 632 (0.32%)
occurrences (all)	3	1	2
Dry eye			
subjects affected / exposed	3 / 93 (3.23%)	0 / 18 (0.00%)	5 / 632 (0.79%)
occurrences (all)	3	0	5
Visual impairment			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	7 / 632 (1.11%)
occurrences (all)	1	0	7
Gastrointestinal disorders			
Angular cheilitis			
subjects affected / exposed	2 / 93 (2.15%)	1 / 18 (5.56%)	2 / 632 (0.32%)
occurrences (all)	3	1	2
Abdominal pain			
subjects affected / exposed	28 / 93 (30.11%)	1 / 18 (5.56%)	113 / 632 (17.88%)
occurrences (all)	34	1	152
Abdominal pain upper			
subjects affected / exposed	12 / 93 (12.90%)	3 / 18 (16.67%)	56 / 632 (8.86%)
occurrences (all)	14	3	69
Constipation			
subjects affected / exposed	23 / 93 (24.73%)	0 / 18 (0.00%)	158 / 632 (25.00%)
occurrences (all)	27	0	235
Dental cyst			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	0 / 632 (0.00%)
occurrences (all)	1	1	0
Diarrhoea			

subjects affected / exposed	52 / 93 (55.91%)	4 / 18 (22.22%)	282 / 632 (44.62%)
occurrences (all)	104	5	539
Haemorrhoids			
subjects affected / exposed	7 / 93 (7.53%)	1 / 18 (5.56%)	22 / 632 (3.48%)
occurrences (all)	7	1	24
Dysphagia			
subjects affected / exposed	4 / 93 (4.30%)	0 / 18 (0.00%)	17 / 632 (2.69%)
occurrences (all)	8	0	24
Gingival bleeding			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	9 / 632 (1.42%)
occurrences (all)	3	0	9
Dyspepsia			
subjects affected / exposed	7 / 93 (7.53%)	1 / 18 (5.56%)	35 / 632 (5.54%)
occurrences (all)	9	1	43
Nausea			
subjects affected / exposed	53 / 93 (56.99%)	0 / 18 (0.00%)	298 / 632 (47.15%)
occurrences (all)	106	0	589
Palatal ulcer			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	0 / 632 (0.00%)
occurrences (all)	1	1	0
Rectal haemorrhage			
subjects affected / exposed	4 / 93 (4.30%)	1 / 18 (5.56%)	18 / 632 (2.85%)
occurrences (all)	4	1	22
Vomiting			
subjects affected / exposed	29 / 93 (31.18%)	1 / 18 (5.56%)	152 / 632 (24.05%)
occurrences (all)	46	1	243
Stomatitis			
subjects affected / exposed	24 / 93 (25.81%)	3 / 18 (16.67%)	144 / 632 (22.78%)
occurrences (all)	36	3	225
Dry mouth			
subjects affected / exposed	3 / 93 (3.23%)	0 / 18 (0.00%)	19 / 632 (3.01%)
occurrences (all)	3	0	21
Toothache			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	23 / 632 (3.64%)
occurrences (all)	0	0	26
Eructation			



subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences (all)	0	0	2
Gastrooesophageal reflux disease			
subjects affected / exposed	4 / 93 (4.30%)	0 / 18 (0.00%)	25 / 632 (3.96%)
occurrences (all)	4	0	27
Odynophagia			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	5 / 632 (0.79%)
occurrences (all)	2	0	5
Cheilitis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	17 / 632 (2.69%)
occurrences (all)	2	0	22
Anal haemorrhage			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	9 / 632 (1.42%)
occurrences (all)	3	0	11
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences (all)	1	0	3
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	9 / 93 (9.68%)	2 / 18 (11.11%)	63 / 632 (9.97%)
occurrences (all)	10	2	64
Dermatitis			
subjects affected / exposed	2 / 93 (2.15%)	1 / 18 (5.56%)	4 / 632 (0.63%)
occurrences (all)	2	1	5
Nail ridging			
subjects affected / exposed	2 / 93 (2.15%)	1 / 18 (5.56%)	3 / 632 (0.47%)
occurrences (all)	2	1	3
Erythema			
subjects affected / exposed	11 / 93 (11.83%)	1 / 18 (5.56%)	21 / 632 (3.32%)
occurrences (all)	19	4	22
Eczema			

subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	4 / 632 (0.63%)
occurrences (all)	2	0	4
Dry skin			
subjects affected / exposed	21 / 93 (22.58%)	3 / 18 (16.67%)	44 / 632 (6.96%)
occurrences (all)	27	3	54
Dermatitis contact			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	0 / 632 (0.00%)
occurrences (all)	1	1	0
Dermatitis acneiform			
subjects affected / exposed	12 / 93 (12.90%)	0 / 18 (0.00%)	10 / 632 (1.58%)
occurrences (all)	14	0	11
Onychoclasia			
subjects affected / exposed	3 / 93 (3.23%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences (all)	3	0	1
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	16 / 93 (17.20%)	4 / 18 (22.22%)	98 / 632 (15.51%)
occurrences (all)	19	5	147
Photosensitivity reaction			
subjects affected / exposed	10 / 93 (10.75%)	0 / 18 (0.00%)	4 / 632 (0.63%)
occurrences (all)	11	0	4
Pruritus			
subjects affected / exposed	10 / 93 (10.75%)	2 / 18 (11.11%)	34 / 632 (5.38%)
occurrences (all)	10	2	42
Rash			
subjects affected / exposed	20 / 93 (21.51%)	0 / 18 (0.00%)	43 / 632 (6.80%)
occurrences (all)	24	0	52
Rash erythematous			
subjects affected / exposed	3 / 93 (3.23%)	0 / 18 (0.00%)	6 / 632 (0.95%)
occurrences (all)	4	0	6
Rash macular			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	3	0	0
Skin disorder			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences (all)	2	0	1

Skin fissures			
subjects affected / exposed	8 / 93 (8.60%)	0 / 18 (0.00%)	7 / 632 (1.11%)
occurrences (all)	12	0	7
Skin toxicity			
subjects affected / exposed	6 / 93 (6.45%)	0 / 18 (0.00%)	4 / 632 (0.63%)
occurrences (all)	9	0	5
Decubitus ulcer			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	1	0	0
Dermal cyst			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	2	0	0
Rosacea			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	2	0	0
Rash maculo-papular			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	8 / 632 (1.27%)
occurrences (all)	2	0	12
Erythema nodosum			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	1	0	0
Hair texture abnormal			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	1	0	0
Skin exfoliation			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	6 / 632 (0.95%)
occurrences (all)	1	0	6
Hand dermatitis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	1 / 632 (0.16%)
occurrences (all)	1	0	1
Blister			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences (all)	1	0	2
Acne			
subjects affected / exposed	5 / 93 (5.38%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences (all)	7	0	3

Urticaria subjects affected / exposed occurrences (all)	2 / 93 (2.15%) 2	0 / 18 (0.00%) 0	8 / 632 (1.27%) 14
Renal and urinary disorders			
Dysuria subjects affected / exposed occurrences (all)	3 / 93 (3.23%) 3	1 / 18 (5.56%) 1	20 / 632 (3.16%) 21
Proteinuria subjects affected / exposed occurrences (all)	2 / 93 (2.15%) 2	0 / 18 (0.00%) 0	40 / 632 (6.33%) 56
Renal colic subjects affected / exposed occurrences (all)	2 / 93 (2.15%) 2	0 / 18 (0.00%) 0	0 / 632 (0.00%) 0
Nephrolithiasis subjects affected / exposed occurrences (all)	1 / 93 (1.08%) 1	0 / 18 (0.00%) 0	0 / 632 (0.00%) 0
Endocrine disorders			
Hyperthyroidism subjects affected / exposed occurrences (all)	1 / 93 (1.08%) 1	0 / 18 (0.00%) 0	18 / 632 (2.85%) 19
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 93 (1.08%) 1	0 / 18 (0.00%) 0	26 / 632 (4.11%) 34
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	28 / 93 (30.11%) 48	3 / 18 (16.67%) 5	74 / 632 (11.71%) 100
Back pain subjects affected / exposed occurrences (all)	15 / 93 (16.13%) 17	2 / 18 (11.11%) 2	45 / 632 (7.12%) 59
Bone pain subjects affected / exposed occurrences (all)	1 / 93 (1.08%) 1	1 / 18 (5.56%) 1	10 / 632 (1.58%) 10
Muscle spasms subjects affected / exposed occurrences (all)	4 / 93 (4.30%) 4	0 / 18 (0.00%) 0	15 / 632 (2.37%) 15

Pain in extremity subjects affected / exposed occurrences (all)	8 / 93 (8.60%) 11	0 / 18 (0.00%) 0	40 / 632 (6.33%) 50
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	2 / 93 (2.15%) 2	0 / 18 (0.00%) 0	10 / 632 (1.58%) 13
Myalgia subjects affected / exposed occurrences (all)	13 / 93 (13.98%) 18	1 / 18 (5.56%) 1	28 / 632 (4.43%) 34
Muscle tightness subjects affected / exposed occurrences (all)	1 / 93 (1.08%) 1	1 / 18 (5.56%) 1	1 / 632 (0.16%) 1
Muscular weakness subjects affected / exposed occurrences (all)	2 / 93 (2.15%) 2	0 / 18 (0.00%) 0	7 / 632 (1.11%) 7
Osteoporosis subjects affected / exposed occurrences (all)	2 / 93 (2.15%) 2	0 / 18 (0.00%) 0	2 / 632 (0.32%) 2
Osteoporotic fracture subjects affected / exposed occurrences (all)	1 / 93 (1.08%) 1	0 / 18 (0.00%) 0	0 / 632 (0.00%) 0
Infections and infestations			
Bronchitis subjects affected / exposed occurrences (all)	2 / 93 (2.15%) 3	1 / 18 (5.56%) 2	17 / 632 (2.69%) 17
Conjunctivitis subjects affected / exposed occurrences (all)	5 / 93 (5.38%) 6	1 / 18 (5.56%) 1	16 / 632 (2.53%) 18
Eye infection subjects affected / exposed occurrences (all)	1 / 93 (1.08%) 1	1 / 18 (5.56%) 1	0 / 632 (0.00%) 0
Oral herpes subjects affected / exposed occurrences (all)	3 / 93 (3.23%) 3	1 / 18 (5.56%) 1	7 / 632 (1.11%) 7
Nasopharyngitis			

subjects affected / exposed	4 / 93 (4.30%)	1 / 18 (5.56%)	42 / 632 (6.65%)
occurrences (all)	4	1	56
Onychomycosis			
subjects affected / exposed	2 / 93 (2.15%)	2 / 18 (11.11%)	6 / 632 (0.95%)
occurrences (all)	2	2	8
Folliculitis			
subjects affected / exposed	8 / 93 (8.60%)	0 / 18 (0.00%)	4 / 632 (0.63%)
occurrences (all)	11	0	5
Paronychia			
subjects affected / exposed	8 / 93 (8.60%)	0 / 18 (0.00%)	4 / 632 (0.63%)
occurrences (all)	22	0	4
Rhinitis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	23 / 632 (3.64%)
occurrences (all)	1	0	23
Tracheitis			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	1 / 632 (0.16%)
occurrences (all)	1	1	1
Urinary tract infection			
subjects affected / exposed	6 / 93 (6.45%)	1 / 18 (5.56%)	42 / 632 (6.65%)
occurrences (all)	6	1	52
Upper respiratory tract infection			
subjects affected / exposed	5 / 93 (5.38%)	2 / 18 (11.11%)	27 / 632 (4.27%)
occurrences (all)	6	2	40
Gastroenteritis			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	6 / 632 (0.95%)
occurrences (all)	2	0	6
Staphylococcal infection			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	1	0	0
Vascular device infection			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	8 / 632 (1.27%)
occurrences (all)	1	0	8
Febrile infection			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	2 / 632 (0.32%)
occurrences (all)	1	0	2
Catheter site infection			

subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences (all)	1	0	3
Device related infection			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	8 / 632 (1.27%)
occurrences (all)	3	0	10
Vulvitis			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	1	0	0
Anal abscess			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	0 / 632 (0.00%)
occurrences (all)	1	0	0
Cystitis			
subjects affected / exposed	0 / 93 (0.00%)	0 / 18 (0.00%)	8 / 632 (1.27%)
occurrences (all)	0	0	9
Metabolism and nutrition disorders			
Food craving			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	0 / 632 (0.00%)
occurrences (all)	1	1	0
Decreased appetite			
subjects affected / exposed	20 / 93 (21.51%)	0 / 18 (0.00%)	130 / 632 (20.57%)
occurrences (all)	26	0	171
Hyperglycaemia			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	29 / 632 (4.59%)
occurrences (all)	1	0	43
Hypoalbuminaemia			
subjects affected / exposed	1 / 93 (1.08%)	1 / 18 (5.56%)	17 / 632 (2.69%)
occurrences (all)	1	1	23
Hypocalcaemia			
subjects affected / exposed	4 / 93 (4.30%)	1 / 18 (5.56%)	18 / 632 (2.85%)
occurrences (all)	5	1	37
Hypomagnesaemia			
subjects affected / exposed	7 / 93 (7.53%)	0 / 18 (0.00%)	9 / 632 (1.42%)
occurrences (all)	9	0	9
Hypophosphataemia			
subjects affected / exposed	3 / 93 (3.23%)	0 / 18 (0.00%)	10 / 632 (1.58%)
occurrences (all)	3	0	10

Hypokalaemia			
subjects affected / exposed	13 / 93 (13.98%)	1 / 18 (5.56%)	68 / 632 (10.76%)
occurrences (all)	20	1	91
Dehydration			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	11 / 632 (1.74%)
occurrences (all)	3	0	11
Hyperkalaemia			
subjects affected / exposed	1 / 93 (1.08%)	0 / 18 (0.00%)	7 / 632 (1.11%)
occurrences (all)	2	0	9
Hypercalcaemia			
subjects affected / exposed	2 / 93 (2.15%)	0 / 18 (0.00%)	3 / 632 (0.47%)
occurrences (all)	2	0	3

<b>Non-serious adverse events</b>	Cohort 2 (MP):5-FU/LV or capecitabine,bevacizumab,atezolizumab	Cohort 2 Control (MP): 5-FU/LV or capecitabin, bevacizumab	Early Progressing BRAFmut Cohort
Total subjects affected by non-serious adverse events			
subjects affected / exposed	270 / 293 (92.15%)	120 / 143 (83.92%)	11 / 11 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Melanocytic naevus			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Cancer pain			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Tumour associated fever			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	49 / 293 (16.72%)	15 / 143 (10.49%)	1 / 11 (9.09%)
occurrences (all)	70	19	1
Hypotension			
subjects affected / exposed	3 / 293 (1.02%)	1 / 143 (0.70%)	2 / 11 (18.18%)
occurrences (all)	3	1	2
Phlebitis			



subjects affected / exposed occurrences (all)	0 / 293 (0.00%) 0	0 / 143 (0.00%) 0	1 / 11 (9.09%) 1
General disorders and administration site conditions			
Face oedema			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	3	0	0
Asthenia			
subjects affected / exposed	40 / 293 (13.65%)	12 / 143 (8.39%)	1 / 11 (9.09%)
occurrences (all)	58	20	1
Fatigue			
subjects affected / exposed	52 / 293 (17.75%)	23 / 143 (16.08%)	3 / 11 (27.27%)
occurrences (all)	77	27	3
Influenza like illness			
subjects affected / exposed	9 / 293 (3.07%)	3 / 143 (2.10%)	1 / 11 (9.09%)
occurrences (all)	10	3	1
Mucosal inflammation			
subjects affected / exposed	20 / 293 (6.83%)	7 / 143 (4.90%)	2 / 11 (18.18%)
occurrences (all)	26	9	3
Pain			
subjects affected / exposed	4 / 293 (1.37%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	4	1	0
Pyrexia			
subjects affected / exposed	32 / 293 (10.92%)	13 / 143 (9.09%)	0 / 11 (0.00%)
occurrences (all)	52	14	0
Oedema peripheral			
subjects affected / exposed	8 / 293 (2.73%)	2 / 143 (1.40%)	2 / 11 (18.18%)
occurrences (all)	8	2	3
Catheter site pain			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
General physical health deterioration			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Malaise			

subjects affected / exposed occurrences (all)	5 / 293 (1.71%) 5	1 / 143 (0.70%) 1	0 / 11 (0.00%) 0
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	2 / 293 (0.68%) 2	1 / 143 (0.70%) 1	0 / 11 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Chronic obstructive pulmonary disease subjects affected / exposed occurrences (all)	2 / 293 (0.68%) 2	1 / 143 (0.70%) 1	0 / 11 (0.00%) 0
Cough subjects affected / exposed occurrences (all)	30 / 293 (10.24%) 39	9 / 143 (6.29%) 11	0 / 11 (0.00%) 0
Dysphonia subjects affected / exposed occurrences (all)	15 / 293 (5.12%) 18	3 / 143 (2.10%) 3	0 / 11 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	12 / 293 (4.10%) 12	3 / 143 (2.10%) 3	2 / 11 (18.18%) 3
Pulmonary embolism subjects affected / exposed occurrences (all)	3 / 293 (1.02%) 3	1 / 143 (0.70%) 1	0 / 11 (0.00%) 0
Nasal ulcer subjects affected / exposed occurrences (all)	0 / 293 (0.00%) 0	0 / 143 (0.00%) 0	0 / 11 (0.00%) 0
Nasal dryness subjects affected / exposed occurrences (all)	2 / 293 (0.68%) 2	0 / 143 (0.00%) 0	1 / 11 (9.09%) 1
Epistaxis subjects affected / exposed occurrences (all)	23 / 293 (7.85%) 29	16 / 143 (11.19%) 20	3 / 11 (27.27%) 3
Hiccups subjects affected / exposed occurrences (all)	0 / 293 (0.00%) 0	1 / 143 (0.70%) 1	0 / 11 (0.00%) 0
Oropharyngeal pain			

subjects affected / exposed occurrences (all)	6 / 293 (2.05%) 9	3 / 143 (2.10%) 4	0 / 11 (0.00%) 0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	4 / 293 (1.37%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	4	1	0
Insomnia			
subjects affected / exposed	10 / 293 (3.41%)	3 / 143 (2.10%)	2 / 11 (18.18%)
occurrences (all)	10	3	2
Depression			
subjects affected / exposed	3 / 293 (1.02%)	5 / 143 (3.50%)	2 / 11 (18.18%)
occurrences (all)	3	5	2
Product issues			
Device occlusion			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	1 / 11 (9.09%)
occurrences (all)	0	1	1
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	8 / 293 (2.73%)	6 / 143 (4.20%)	0 / 11 (0.00%)
occurrences (all)	14	9	0
Amylase increased			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	2	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	10 / 293 (3.41%)	6 / 143 (4.20%)	0 / 11 (0.00%)
occurrences (all)	13	7	0
Blood alkaline phosphatase increased			
subjects affected / exposed	5 / 293 (1.71%)	4 / 143 (2.80%)	0 / 11 (0.00%)
occurrences (all)	5	5	0
Ejection fraction decreased			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			

subjects affected / exposed	4 / 293 (1.37%)	1 / 143 (0.70%)	1 / 11 (9.09%)
occurrences (all)	4	4	1
Blood bilirubin increased			
subjects affected / exposed	8 / 293 (2.73%)	5 / 143 (3.50%)	0 / 11 (0.00%)
occurrences (all)	10	6	0
Lipase increased			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	3	0	1
Neutrophil count decreased			
subjects affected / exposed	7 / 293 (2.39%)	3 / 143 (2.10%)	1 / 11 (9.09%)
occurrences (all)	11	4	1
Platelet count decreased			
subjects affected / exposed	6 / 293 (2.05%)	3 / 143 (2.10%)	0 / 11 (0.00%)
occurrences (all)	19	4	0
Weight increased			
subjects affected / exposed	2 / 293 (0.68%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	3	1	0
Weight decreased			
subjects affected / exposed	11 / 293 (3.75%)	2 / 143 (1.40%)	0 / 11 (0.00%)
occurrences (all)	12	3	0
Cardiac murmur			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Blood potassium decreased			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
C-reactive protein increased			
subjects affected / exposed	3 / 293 (1.02%)	1 / 143 (0.70%)	1 / 11 (9.09%)
occurrences (all)	3	1	1
Body temperature increased			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
White blood cell count decreased			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Blood lactate dehydrogenase			

increased subjects affected / exposed occurrences (all)	3 / 293 (1.02%) 3	2 / 143 (1.40%) 2	0 / 11 (0.00%) 0
Injury, poisoning and procedural complications			
Infusion related reaction subjects affected / exposed occurrences (all)	10 / 293 (3.41%) 12	0 / 143 (0.00%) 0	0 / 11 (0.00%) 0
Lumbar vertebral fracture subjects affected / exposed occurrences (all)	0 / 293 (0.00%) 0	1 / 143 (0.70%) 1	1 / 11 (9.09%) 1
Sunburn subjects affected / exposed occurrences (all)	0 / 293 (0.00%) 0	1 / 143 (0.70%) 1	3 / 11 (27.27%) 3
Gastrointestinal stoma complication subjects affected / exposed occurrences (all)	1 / 293 (0.34%) 1	0 / 143 (0.00%) 0	1 / 11 (9.09%) 1
Stoma site pain subjects affected / exposed occurrences (all)	1 / 293 (0.34%) 2	0 / 143 (0.00%) 0	0 / 11 (0.00%) 0
Wound dehiscence subjects affected / exposed occurrences (all)	3 / 293 (1.02%) 3	0 / 143 (0.00%) 0	0 / 11 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	6 / 293 (2.05%) 7	1 / 143 (0.70%) 1	0 / 11 (0.00%) 0
Dysgeusia subjects affected / exposed occurrences (all)	8 / 293 (2.73%) 8	3 / 143 (2.10%) 3	1 / 11 (9.09%) 1
Headache subjects affected / exposed occurrences (all)	24 / 293 (8.19%) 83	5 / 143 (3.50%) 15	0 / 11 (0.00%) 0
Peripheral motor neuropathy subjects affected / exposed occurrences (all)	3 / 293 (1.02%) 3	0 / 143 (0.00%) 0	0 / 11 (0.00%) 0
Neurotoxicity			

subjects affected / exposed	2 / 293 (0.68%)	2 / 143 (1.40%)	0 / 11 (0.00%)
occurrences (all)	3	3	0
Paraesthesia			
subjects affected / exposed	18 / 293 (6.14%)	10 / 143 (6.99%)	0 / 11 (0.00%)
occurrences (all)	21	11	0
Neuropathy peripheral			
subjects affected / exposed	18 / 293 (6.14%)	9 / 143 (6.29%)	0 / 11 (0.00%)
occurrences (all)	21	9	0
Peripheral sensory neuropathy			
subjects affected / exposed	32 / 293 (10.92%)	15 / 143 (10.49%)	0 / 11 (0.00%)
occurrences (all)	38	16	0
Polyneuropathy			
subjects affected / exposed	6 / 293 (2.05%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	6	2	0
Restless legs syndrome			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	1 / 11 (9.09%)
occurrences (all)	0	1	1
Somnolence			
subjects affected / exposed	4 / 293 (1.37%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	5	0	0
Taste disorder			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	1 / 11 (9.09%)
occurrences (all)	1	1	1
Sensory loss			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Ageusia			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	21 / 293 (7.17%)	8 / 143 (5.59%)	1 / 11 (9.09%)
occurrences (all)	27	13	1
Leukopenia			
subjects affected / exposed	4 / 293 (1.37%)	3 / 143 (2.10%)	0 / 11 (0.00%)
occurrences (all)	8	3	0

Neutropenia			
subjects affected / exposed	12 / 293 (4.10%)	8 / 143 (5.59%)	0 / 11 (0.00%)
occurrences (all)	12	17	0
Thrombocytopenia			
subjects affected / exposed	10 / 293 (3.41%)	4 / 143 (2.80%)	0 / 11 (0.00%)
occurrences (all)	12	10	0
Ear and labyrinth disorders			
Auditory meatus external erosion			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Eye disorders			
Cataract			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	3	0	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Lacrimation increased			
subjects affected / exposed	4 / 293 (1.37%)	5 / 143 (3.50%)	0 / 11 (0.00%)
occurrences (all)	5	5	0
Periorbital oedema			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	2	0	0
Dry eye			
subjects affected / exposed	1 / 293 (0.34%)	2 / 143 (1.40%)	1 / 11 (9.09%)
occurrences (all)	1	2	1
Visual impairment			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	2	0	0
Gastrointestinal disorders			
Angular cheilitis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	39 / 293 (13.31%)	12 / 143 (8.39%)	4 / 11 (36.36%)
occurrences (all)	44	15	5
Abdominal pain upper			

subjects affected / exposed	18 / 293 (6.14%)	11 / 143 (7.69%)	0 / 11 (0.00%)
occurrences (all)	22	15	0
Constipation			
subjects affected / exposed	38 / 293 (12.97%)	17 / 143 (11.89%)	1 / 11 (9.09%)
occurrences (all)	48	26	1
Dental cyst			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	78 / 293 (26.62%)	21 / 143 (14.69%)	5 / 11 (45.45%)
occurrences (all)	120	36	5
Haemorrhoids			
subjects affected / exposed	5 / 293 (1.71%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	5	2	0
Dysphagia			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	1	1	0
Gingival bleeding			
subjects affected / exposed	5 / 293 (1.71%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	5	0	0
Dyspepsia			
subjects affected / exposed	10 / 293 (3.41%)	4 / 143 (2.80%)	0 / 11 (0.00%)
occurrences (all)	12	4	0
Nausea			
subjects affected / exposed	64 / 293 (21.84%)	27 / 143 (18.88%)	3 / 11 (27.27%)
occurrences (all)	134	41	4
Palatal ulcer			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	6 / 293 (2.05%)	4 / 143 (2.80%)	1 / 11 (9.09%)
occurrences (all)	6	6	1
Vomiting			
subjects affected / exposed	39 / 293 (13.31%)	8 / 143 (5.59%)	4 / 11 (36.36%)
occurrences (all)	61	11	5
Stomatitis			



subjects affected / exposed	35 / 293 (11.95%)	11 / 143 (7.69%)	1 / 11 (9.09%)
occurrences (all)	50	19	2
Dry mouth			
subjects affected / exposed	4 / 293 (1.37%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	4	0	1
Toothache			
subjects affected / exposed	8 / 293 (2.73%)	2 / 143 (1.40%)	0 / 11 (0.00%)
occurrences (all)	8	2	0
Eructation			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	6 / 293 (2.05%)	1 / 143 (0.70%)	2 / 11 (18.18%)
occurrences (all)	8	1	2
Odynophagia			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Cheilitis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Flatulence			
subjects affected / exposed	2 / 293 (0.68%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	2	1	0
Anal haemorrhage			
subjects affected / exposed	4 / 293 (1.37%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	5	0	1
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	8 / 293 (2.73%)	2 / 143 (1.40%)	0 / 11 (0.00%)
occurrences (all)	8	2	0
Dermatitis			

subjects affected / exposed	3 / 293 (1.02%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	3	1	0
Nail ridging			
subjects affected / exposed	0 / 293 (0.00%)	3 / 143 (2.10%)	1 / 11 (9.09%)
occurrences (all)	0	3	1
Erythema			
subjects affected / exposed	11 / 293 (3.75%)	2 / 143 (1.40%)	2 / 11 (18.18%)
occurrences (all)	12	2	4
Eczema			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	2	0	0
Dry skin			
subjects affected / exposed	18 / 293 (6.14%)	3 / 143 (2.10%)	3 / 11 (27.27%)
occurrences (all)	21	6	3
Dermatitis contact			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	4 / 293 (1.37%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	4	0	1
Onychoclasia			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	44 / 293 (15.02%)	25 / 143 (17.48%)	2 / 11 (18.18%)
occurrences (all)	66	40	2
Photosensitivity reaction			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	20 / 293 (6.83%)	6 / 143 (4.20%)	3 / 11 (27.27%)
occurrences (all)	25	6	3
Rash			
subjects affected / exposed	24 / 293 (8.19%)	1 / 143 (0.70%)	4 / 11 (36.36%)
occurrences (all)	30	1	4

Rash erythematous			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	2	0	0
Rash macular			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Skin disorder			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	2	0	1
Skin toxicity			
subjects affected / exposed	4 / 293 (1.37%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	5	0	1
Decubitus ulcer			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Dermal cyst			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	2
Rosacea			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	2
Rash maculo-papular			
subjects affected / exposed	4 / 293 (1.37%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	6	0	1
Erythema nodosum			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Hair texture abnormal			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Skin exfoliation			
subjects affected / exposed	5 / 293 (1.71%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	5	0	0

Hand dermatitis subjects affected / exposed occurrences (all)	1 / 293 (0.34%) 1	0 / 143 (0.00%) 0	1 / 11 (9.09%) 1
Blister subjects affected / exposed occurrences (all)	1 / 293 (0.34%) 1	0 / 143 (0.00%) 0	1 / 11 (9.09%) 1
Acne subjects affected / exposed occurrences (all)	0 / 293 (0.00%) 0	1 / 143 (0.70%) 1	3 / 11 (27.27%) 4
Urticaria subjects affected / exposed occurrences (all)	4 / 293 (1.37%) 5	0 / 143 (0.00%) 0	1 / 11 (9.09%) 1
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all)	2 / 293 (0.68%) 2	1 / 143 (0.70%) 1	0 / 11 (0.00%) 0
Proteinuria subjects affected / exposed occurrences (all)	17 / 293 (5.80%) 25	4 / 143 (2.80%) 4	0 / 11 (0.00%) 0
Renal colic subjects affected / exposed occurrences (all)	0 / 293 (0.00%) 0	0 / 143 (0.00%) 0	1 / 11 (9.09%) 1
Nephrolithiasis subjects affected / exposed occurrences (all)	0 / 293 (0.00%) 0	0 / 143 (0.00%) 0	1 / 11 (9.09%) 1
Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all)	16 / 293 (5.46%) 17	0 / 143 (0.00%) 0	0 / 11 (0.00%) 0
Hypothyroidism subjects affected / exposed occurrences (all)	24 / 293 (8.19%) 32	1 / 143 (0.70%) 1	0 / 11 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	50 / 293 (17.06%) 67	8 / 143 (5.59%) 10	5 / 11 (45.45%) 5

Back pain			
subjects affected / exposed	22 / 293 (7.51%)	9 / 143 (6.29%)	3 / 11 (27.27%)
occurrences (all)	32	9	4
Bone pain			
subjects affected / exposed	6 / 293 (2.05%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	6	0	0
Muscle spasms			
subjects affected / exposed	5 / 293 (1.71%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	5	0	0
Pain in extremity			
subjects affected / exposed	13 / 293 (4.44%)	8 / 143 (5.59%)	0 / 11 (0.00%)
occurrences (all)	18	9	0
Musculoskeletal chest pain			
subjects affected / exposed	5 / 293 (1.71%)	2 / 143 (1.40%)	0 / 11 (0.00%)
occurrences (all)	6	2	0
Myalgia			
subjects affected / exposed	15 / 293 (5.12%)	3 / 143 (2.10%)	1 / 11 (9.09%)
occurrences (all)	17	3	1
Muscle tightness			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	1	0	0
Muscular weakness			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	2 / 11 (18.18%)
occurrences (all)	0	0	2
Osteoporosis			
subjects affected / exposed	0 / 293 (0.00%)	2 / 143 (1.40%)	1 / 11 (9.09%)
occurrences (all)	0	2	1
Osteoporotic fracture			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Infections and infestations			
Bronchitis			
subjects affected / exposed	5 / 293 (1.71%)	3 / 143 (2.10%)	0 / 11 (0.00%)
occurrences (all)	5	3	0
Conjunctivitis			

subjects affected / exposed	5 / 293 (1.71%)	2 / 143 (1.40%)	0 / 11 (0.00%)
occurrences (all)	6	2	0
Eye infection			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	15 / 293 (5.12%)	10 / 143 (6.99%)	1 / 11 (9.09%)
occurrences (all)	21	12	1
Onychomycosis			
subjects affected / exposed	2 / 293 (0.68%)	2 / 143 (1.40%)	0 / 11 (0.00%)
occurrences (all)	4	2	0
Folliculitis			
subjects affected / exposed	2 / 293 (0.68%)	1 / 143 (0.70%)	2 / 11 (18.18%)
occurrences (all)	3	1	3
Paronychia			
subjects affected / exposed	2 / 293 (0.68%)	1 / 143 (0.70%)	2 / 11 (18.18%)
occurrences (all)	2	1	8
Rhinitis			
subjects affected / exposed	5 / 293 (1.71%)	3 / 143 (2.10%)	0 / 11 (0.00%)
occurrences (all)	5	3	0
Tracheitis			
subjects affected / exposed	0 / 293 (0.00%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	12 / 293 (4.10%)	4 / 143 (2.80%)	1 / 11 (9.09%)
occurrences (all)	13	4	1
Upper respiratory tract infection			
subjects affected / exposed	12 / 293 (4.10%)	2 / 143 (1.40%)	0 / 11 (0.00%)
occurrences (all)	22	2	0
Gastroenteritis			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	1 / 11 (9.09%)
occurrences (all)	1	1	1
Staphylococcal infection			

subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Vascular device infection			
subjects affected / exposed	1 / 293 (0.34%)	1 / 143 (0.70%)	1 / 11 (9.09%)
occurrences (all)	1	1	1
Febrile infection			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Catheter site infection			
subjects affected / exposed	1 / 293 (0.34%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	1	0	1
Device related infection			
subjects affected / exposed	2 / 293 (0.68%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	3	0	0
Vulvitis			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Anal abscess			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	1 / 11 (9.09%)
occurrences (all)	0	0	1
Cystitis			
subjects affected / exposed	2 / 293 (0.68%)	1 / 143 (0.70%)	0 / 11 (0.00%)
occurrences (all)	2	1	0
Metabolism and nutrition disorders			
Food craving			
subjects affected / exposed	0 / 293 (0.00%)	0 / 143 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	24 / 293 (8.19%)	14 / 143 (9.79%)	2 / 11 (18.18%)
occurrences (all)	26	15	2
Hyperglycaemia			
subjects affected / exposed	5 / 293 (1.71%)	2 / 143 (1.40%)	0 / 11 (0.00%)
occurrences (all)	6	5	0
Hypoalbuminaemia			
subjects affected / exposed	2 / 293 (0.68%)	2 / 143 (1.40%)	0 / 11 (0.00%)
occurrences (all)	2	4	0

Hypocalcaemia subjects affected / exposed occurrences (all)	5 / 293 (1.71%) 10	6 / 143 (4.20%) 10	0 / 11 (0.00%) 0
Hypomagnesaemia subjects affected / exposed occurrences (all)	4 / 293 (1.37%) 4	0 / 143 (0.00%) 0	1 / 11 (9.09%) 1
Hypophosphataemia subjects affected / exposed occurrences (all)	2 / 293 (0.68%) 2	3 / 143 (2.10%) 3	0 / 11 (0.00%) 0
Hypokalaemia subjects affected / exposed occurrences (all)	6 / 293 (2.05%) 7	8 / 143 (5.59%) 9	2 / 11 (18.18%) 2
Dehydration subjects affected / exposed occurrences (all)	4 / 293 (1.37%) 4	0 / 143 (0.00%) 0	1 / 11 (9.09%) 2
Hyperkalaemia subjects affected / exposed occurrences (all)	4 / 293 (1.37%) 5	1 / 143 (0.70%) 2	1 / 11 (9.09%) 2
Hypercalcaemia subjects affected / exposed occurrences (all)	1 / 293 (0.34%) 1	1 / 143 (0.70%) 1	1 / 11 (9.09%) 1

<b>Non-serious adverse events</b>	Cohort 3 (MP): capecitabine,trastuzumab,pertuzumab	Cohort 3 Control (MP): 5-FU/LV or capecitabin, bevacizumab	Cohort 4 (IP)
Total subjects affected by non-serious adverse events subjects affected / exposed	3 / 3 (100.00%)	2 / 2 (100.00%)	298 / 309 (96.44%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Melanocytic naevus subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	0 / 309 (0.00%) 0
Cancer pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	1 / 309 (0.32%) 1
Tumour associated fever subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	0 / 309 (0.00%) 0



Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	62 / 309 (20.06%)
occurrences (all)	0	0	79
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	8 / 309 (2.59%)
occurrences (all)	0	0	8
Phlebitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences (all)	0	0	2
General disorders and administration site conditions			
Face oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	5 / 309 (1.62%)
occurrences (all)	0	0	5
Asthenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	63 / 309 (20.39%)
occurrences (all)	0	0	111
Fatigue			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	87 / 309 (28.16%)
occurrences (all)	1	0	138
Influenza like illness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	10 / 309 (3.24%)
occurrences (all)	0	0	10
Mucosal inflammation			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	57 / 309 (18.45%)
occurrences (all)	1	0	72
Pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	1	0	3
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	56 / 309 (18.12%)
occurrences (all)	0	0	76
Oedema peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	16 / 309 (5.18%)
occurrences (all)	0	0	18
Catheter site pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences (all)	0	0	2
General physical health deterioration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences (all)	1	0	4
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences (all)	0	0	5
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	27 / 309 (8.74%)
occurrences (all)	0	0	31
Dysphonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	14 / 309 (4.53%)
occurrences (all)	0	0	14
Dyspnoea			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	20 / 309 (6.47%)
occurrences (all)	1	0	21
Pulmonary embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	5 / 309 (1.62%)
occurrences (all)	0	0	5
Nasal ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Nasal dryness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Epistaxis			

subjects affected / exposed	0 / 3 (0.00%)	2 / 2 (100.00%)	61 / 309 (19.74%)
occurrences (all)	0	2	70
Hiccups			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	8 / 309 (2.59%)
occurrences (all)	0	0	9
Oropharyngeal pain			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	5 / 309 (1.62%)
occurrences (all)	1	0	5
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	9 / 309 (2.91%)
occurrences (all)	0	0	9
Insomnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	12 / 309 (3.88%)
occurrences (all)	0	0	13
Depression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences (all)	0	0	2
Product issues			
Device occlusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences (all)	0	0	3
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	17 / 309 (5.50%)
occurrences (all)	0	0	20
Amylase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	8 / 309 (2.59%)
occurrences (all)	0	0	8
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	20 / 309 (6.47%)
occurrences (all)	0	0	22
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	12 / 309 (3.88%)
occurrences (all)	0	0	16
Ejection fraction decreased			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	6 / 309 (1.94%)
occurrences (all)	0	0	7
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	32 / 309 (10.36%)
occurrences (all)	1	0	40
Blood creatinine increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	7 / 309 (2.27%)
occurrences (all)	0	0	7
Blood bilirubin increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences (all)	0	0	4
Lipase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	9 / 309 (2.91%)
occurrences (all)	0	0	12
Neutrophil count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	28 / 309 (9.06%)
occurrences (all)	0	0	42
Platelet count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	27 / 309 (8.74%)
occurrences (all)	0	0	37
Weight increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	8 / 309 (2.59%)
occurrences (all)	0	0	14
Weight decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	30 / 309 (9.71%)
occurrences (all)	0	0	31
Cardiac murmur			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Blood potassium decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1

Body temperature increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	0 / 309 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1	0 / 2 (0.00%) 0	6 / 309 (1.94%) 8
Blood lactate dehydrogenase increased subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	4 / 309 (1.29%) 4
Injury, poisoning and procedural complications			
Infusion related reaction subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	11 / 309 (3.56%) 17
Lumbar vertebral fracture subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	0 / 309 (0.00%) 0
Sunburn subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	0 / 309 (0.00%) 0
Gastrointestinal stoma complication subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	0 / 309 (0.00%) 0
Stoma site pain subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	0 / 309 (0.00%) 0
Wound dehiscence subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	1 / 309 (0.32%) 1
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	12 / 309 (3.88%) 12
Dysgeusia subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	21 / 309 (6.80%) 26
Headache			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	28 / 309 (9.06%)
occurrences (all)	0	0	50
Peripheral motor neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	11 / 309 (3.56%)
occurrences (all)	0	0	12
Neurotoxicity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	27 / 309 (8.74%)
occurrences (all)	0	0	46
Paraesthesia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	43 / 309 (13.92%)
occurrences (all)	0	0	57
Neuropathy peripheral			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	57 / 309 (18.45%)
occurrences (all)	0	0	84
Peripheral sensory neuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	58 / 309 (18.77%)
occurrences (all)	0	0	91
Polyneuropathy			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	9 / 309 (2.91%)
occurrences (all)	0	0	12
Restless legs syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	2
Somnolence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Sensory loss			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Ageusia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences (all)	0	0	4
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	49 / 309 (15.86%)
occurrences (all)	0	0	62
Leukopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	11 / 309 (3.56%)
occurrences (all)	0	0	14
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	78 / 309 (25.24%)
occurrences (all)	0	0	123
Thrombocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	22 / 309 (7.12%)
occurrences (all)	0	0	45
Ear and labyrinth disorders			
Auditory meatus external erosion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences (all)	0	0	4
Conjunctival haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences (all)	0	0	2
Periorbital oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences (all)	0	0	2
Visual impairment			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	1	0	1
Gastrointestinal disorders			

Angular cheilitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	45 / 309 (14.56%)
occurrences (all)	0	0	56
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	20 / 309 (6.47%)
occurrences (all)	0	0	21
Constipation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 2 (50.00%)	58 / 309 (18.77%)
occurrences (all)	0	1	74
Dental cyst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	2 / 3 (66.67%)	0 / 2 (0.00%)	134 / 309 (43.37%)
occurrences (all)	5	0	276
Haemorrhoids			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	7 / 309 (2.27%)
occurrences (all)	0	0	7
Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	10 / 309 (3.24%)
occurrences (all)	0	0	10
Gingival bleeding			
subjects affected / exposed	0 / 3 (0.00%)	1 / 2 (50.00%)	0 / 309 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	19 / 309 (6.15%)
occurrences (all)	0	0	19
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	129 / 309 (41.75%)
occurrences (all)	0	0	246
Palatal ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0



Rectal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences (all)	0	0	4
Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	66 / 309 (21.36%)
occurrences (all)	0	0	101
Stomatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	40 / 309 (12.94%)
occurrences (all)	0	0	52
Dry mouth			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	9 / 309 (2.91%)
occurrences (all)	0	0	9
Toothache			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences (all)	1	0	3
Eruption			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences (all)	0	0	2
Odynophagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences (all)	0	0	2
Cheilitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences (all)	0	0	4
Flatulence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	6 / 309 (1.94%)
occurrences (all)	0	0	6
Anal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences (all)	0	0	2
Hepatobiliary disorders			
Hepatomegaly			

subjects affected / exposed occurrences (all)	0 / 3 (0.00%) 0	0 / 2 (0.00%) 0	0 / 309 (0.00%) 0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	19 / 309 (6.15%)
occurrences (all)	0	0	19
Dermatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	2
Nail ridging			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	1	0	0
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences (all)	0	0	4
Eczema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	20 / 309 (6.47%)
occurrences (all)	1	0	20
Dermatitis contact			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	20 / 309 (6.47%)
occurrences (all)	0	0	23
Onychoclasia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysesthesia syndrome			
subjects affected / exposed	3 / 3 (100.00%)	0 / 2 (0.00%)	19 / 309 (6.15%)
occurrences (all)	6	0	19
Photosensitivity reaction			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	16 / 309 (5.18%)
occurrences (all)	0	0	26
Rash			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	38 / 309 (12.30%)
occurrences (all)	0	0	46
Rash erythematous			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Skin disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences (all)	0	0	3
Skin toxicity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Decubitus ulcer			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Dermal cyst			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Rosacea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	5 / 309 (1.62%)
occurrences (all)	0	0	6
Erythema nodosum			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Hair texture abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Skin exfoliation			
subjects affected / exposed	0 / 3 (0.00%)	1 / 2 (50.00%)	0 / 309 (0.00%)
occurrences (all)	0	1	0
Hand dermatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Acne			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences (all)	0	0	6
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	10 / 309 (3.24%)
occurrences (all)	0	0	12
Proteinuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	7 / 309 (2.27%)
occurrences (all)	0	0	12
Renal colic			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hyperthyroidism			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Hypothyroidism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences (all)	0	0	3
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	19 / 309 (6.15%)
occurrences (all)	0	0	22
Back pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	16 / 309 (5.18%)
occurrences (all)	0	0	17
Bone pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences (all)	0	0	4
Muscle spasms			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences (all)	1	0	4
Pain in extremity			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	12 / 309 (3.88%)
occurrences (all)	0	0	14
Musculoskeletal chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	18 / 309 (5.83%)
occurrences (all)	0	0	23
Muscle tightness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	4 / 309 (1.29%)
occurrences (all)	0	0	4
Osteoporosis			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Osteoporotic fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences (all)	0	0	3
Conjunctivitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	5 / 309 (1.62%)
occurrences (all)	0	0	5
Eye infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences (all)	0	0	2
Nasopharyngitis			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	15 / 309 (4.85%)
occurrences (all)	1	0	17
Onychomycosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Paronychia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	6 / 309 (1.94%)
occurrences (all)	0	0	7
Tracheitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0

Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	18 / 309 (5.83%)
occurrences (all)	0	0	25
Upper respiratory tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	12 / 309 (3.88%)
occurrences (all)	0	0	13
Gastroenteritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	5 / 309 (1.62%)
occurrences (all)	0	0	5
Staphylococcal infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Vascular device infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Febrile infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Catheter site infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	1 / 309 (0.32%)
occurrences (all)	0	0	1
Vulvitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Anal abscess			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	2 / 309 (0.65%)
occurrences (all)	1	0	2
Metabolism and nutrition disorders			
Food craving			

subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	47 / 309 (15.21%)
occurrences (all)	0	0	55
Hyperglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	16 / 309 (5.18%)
occurrences (all)	0	0	20
Hypoalbuminaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	6 / 309 (1.94%)
occurrences (all)	0	0	8
Hypocalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	7 / 309 (2.27%)
occurrences (all)	0	0	10
Hypomagnesaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	6 / 309 (1.94%)
occurrences (all)	0	0	7
Hypophosphataemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	6 / 309 (1.94%)
occurrences (all)	0	0	8
Hypokalaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 2 (0.00%)	16 / 309 (5.18%)
occurrences (all)	1	0	18
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences (all)	0	0	4
Hyperkalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	3 / 309 (0.97%)
occurrences (all)	0	0	3
Hypercalcaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 2 (0.00%)	0 / 309 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Cohort 4 (MP): Cobimetinib,atezoliz umab	Cohort 4 Control (MP): 5-FU/LV or capecitabin, bevacizumab	Cohort 1 (Maintenance Phase[MP]):5- FU/LV,cetuximab,ve murafenib
-----------------------------------	--	---	--



Total subjects affected by non-serious adverse events			
subjects affected / exposed	61 / 64 (95.31%)	29 / 34 (85.29%)	40 / 40 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Melanocytic naevus			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Cancer pain			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	0 / 40 (0.00%)
occurrences (all)	0	1	0
Tumour associated fever			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Hypertension			
subjects affected / exposed	3 / 64 (4.69%)	5 / 34 (14.71%)	1 / 40 (2.50%)
occurrences (all)	4	7	1
Hypotension			
subjects affected / exposed	3 / 64 (4.69%)	0 / 34 (0.00%)	4 / 40 (10.00%)
occurrences (all)	3	0	4
Phlebitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	0	0	2
General disorders and administration site conditions			
Face oedema			
subjects affected / exposed	5 / 64 (7.81%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	5	0	0
Asthenia			
subjects affected / exposed	13 / 64 (20.31%)	3 / 34 (8.82%)	5 / 40 (12.50%)
occurrences (all)	18	3	9
Fatigue			
subjects affected / exposed	12 / 64 (18.75%)	7 / 34 (20.59%)	9 / 40 (22.50%)
occurrences (all)	20	8	11
Influenza like illness			
subjects affected / exposed	1 / 64 (1.56%)	1 / 34 (2.94%)	2 / 40 (5.00%)
occurrences (all)	1	1	2
Mucosal inflammation			

subjects affected / exposed	4 / 64 (6.25%)	1 / 34 (2.94%)	7 / 40 (17.50%)
occurrences (all)	5	1	8
Pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	3 / 40 (7.50%)
occurrences (all)	0	0	3
Pyrexia			
subjects affected / exposed	20 / 64 (31.25%)	3 / 34 (8.82%)	8 / 40 (20.00%)
occurrences (all)	27	3	8
Oedema peripheral			
subjects affected / exposed	6 / 64 (9.38%)	1 / 34 (2.94%)	3 / 40 (7.50%)
occurrences (all)	8	1	6
Catheter site pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	1	0	1
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	3 / 40 (7.50%)
occurrences (all)	1	0	3
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	7 / 64 (10.94%)	3 / 34 (8.82%)	5 / 40 (12.50%)
occurrences (all)	7	3	6
Dysphonia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	1	0	1
Dyspnoea			

subjects affected / exposed	2 / 64 (3.13%)	1 / 34 (2.94%)	2 / 40 (5.00%)
occurrences (all)	2	1	2
Pulmonary embolism			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	1 / 40 (2.50%)
occurrences (all)	0	1	2
Nasal ulcer			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Nasal dryness			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	0 / 40 (0.00%)
occurrences (all)	0	1	0
Epistaxis			
subjects affected / exposed	6 / 64 (9.38%)	3 / 34 (8.82%)	4 / 40 (10.00%)
occurrences (all)	6	4	4
Hiccups			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	1	0	1
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	1	0	1
Insomnia			
subjects affected / exposed	3 / 64 (4.69%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	3	0	2
Depression			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	0	0	1
Product issues			
Device occlusion			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Investigations			

Alanine aminotransferase increased			
subjects affected / exposed	12 / 64 (18.75%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	13	0	2
Amylase increased			
subjects affected / exposed	4 / 64 (6.25%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	4	0	1
Aspartate aminotransferase increased			
subjects affected / exposed	15 / 64 (23.44%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	15	0	1
Blood alkaline phosphatase increased			
subjects affected / exposed	6 / 64 (9.38%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	6	0	1
Ejection fraction decreased			
subjects affected / exposed	5 / 64 (7.81%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	6	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	31 / 64 (48.44%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	39	0	0
Blood creatinine increased			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	4 / 40 (10.00%)
occurrences (all)	1	0	6
Blood bilirubin increased			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	1	0	3
Lipase increased			
subjects affected / exposed	5 / 64 (7.81%)	0 / 34 (0.00%)	3 / 40 (7.50%)
occurrences (all)	7	0	3
Neutrophil count decreased			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	2	0	1
Platelet count decreased			
subjects affected / exposed	6 / 64 (9.38%)	1 / 34 (2.94%)	1 / 40 (2.50%)
occurrences (all)	7	1	1
Weight increased			

subjects affected / exposed	3 / 64 (4.69%)	2 / 34 (5.88%)	1 / 40 (2.50%)
occurrences (all)	7	2	1
Weight decreased			
subjects affected / exposed	6 / 64 (9.38%)	0 / 34 (0.00%)	4 / 40 (10.00%)
occurrences (all)	6	0	4
Cardiac murmur			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Blood potassium decreased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Body temperature increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	4	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	2	0	0
Injury, poisoning and procedural complications			
Infusion related reaction			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	2	0	3
Lumbar vertebral fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Sunburn			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	0	0	1
Gastrointestinal stoma complication			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Stoma site pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Wound dehiscence			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	4 / 64 (6.25%)	1 / 34 (2.94%)	4 / 40 (10.00%)
occurrences (all)	4	1	4
Dysgeusia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	4 / 40 (10.00%)
occurrences (all)	0	0	4
Headache			
subjects affected / exposed	6 / 64 (9.38%)	3 / 34 (8.82%)	2 / 40 (5.00%)
occurrences (all)	8	5	2
Peripheral motor neuropathy			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	1	0	3
Neurotoxicity			
subjects affected / exposed	3 / 64 (4.69%)	1 / 34 (2.94%)	3 / 40 (7.50%)
occurrences (all)	3	1	3
Paraesthesia			
subjects affected / exposed	1 / 64 (1.56%)	1 / 34 (2.94%)	4 / 40 (10.00%)
occurrences (all)	1	1	4
Neuropathy peripheral			
subjects affected / exposed	1 / 64 (1.56%)	5 / 34 (14.71%)	1 / 40 (2.50%)
occurrences (all)	2	5	1
Peripheral sensory neuropathy			
subjects affected / exposed	3 / 64 (4.69%)	4 / 34 (11.76%)	4 / 40 (10.00%)
occurrences (all)	6	4	5
Polyneuropathy			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0

Restless legs syndrome subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 34 (0.00%) 0	0 / 40 (0.00%) 0
Somnolence subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 34 (0.00%) 0	2 / 40 (5.00%) 2
Taste disorder subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 34 (0.00%) 0	0 / 40 (0.00%) 0
Sensory loss subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 34 (0.00%) 0	0 / 40 (0.00%) 0
Ageusia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 34 (2.94%) 1	0 / 40 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	8 / 64 (12.50%) 10	1 / 34 (2.94%) 1	7 / 40 (17.50%) 10
Leukopenia subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	1 / 34 (2.94%) 1	1 / 40 (2.50%) 1
Neutropenia subjects affected / exposed occurrences (all)	7 / 64 (10.94%) 9	3 / 34 (8.82%) 4	2 / 40 (5.00%) 2
Thrombocytopenia subjects affected / exposed occurrences (all)	4 / 64 (6.25%) 4	1 / 34 (2.94%) 5	0 / 40 (0.00%) 0
Ear and labyrinth disorders			
Auditory meatus external erosion subjects affected / exposed occurrences (all)	0 / 64 (0.00%) 0	0 / 34 (0.00%) 0	0 / 40 (0.00%) 0
Eye disorders			
Cataract subjects affected / exposed occurrences (all)	3 / 64 (4.69%) 3	0 / 34 (0.00%) 0	4 / 40 (10.00%) 5
Conjunctival haemorrhage			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Lacrimation increased			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Periorbital oedema			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	0 / 40 (0.00%)
occurrences (all)	0	1	0
Visual impairment			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Angular cheilitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	0	0	1
Abdominal pain			
subjects affected / exposed	12 / 64 (18.75%)	5 / 34 (14.71%)	8 / 40 (20.00%)
occurrences (all)	15	5	10
Abdominal pain upper			
subjects affected / exposed	5 / 64 (7.81%)	1 / 34 (2.94%)	2 / 40 (5.00%)
occurrences (all)	6	1	2
Constipation			
subjects affected / exposed	7 / 64 (10.94%)	2 / 34 (5.88%)	5 / 40 (12.50%)
occurrences (all)	9	2	6
Dental cyst			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	40 / 64 (62.50%)	8 / 34 (23.53%)	16 / 40 (40.00%)
occurrences (all)	87	11	43
Haemorrhoids			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	2	0	1



Dysphagia			
subjects affected / exposed	1 / 64 (1.56%)	2 / 34 (5.88%)	2 / 40 (5.00%)
occurrences (all)	1	2	4
Gingival bleeding			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	0	0	3
Dyspepsia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	1	0	1
Nausea			
subjects affected / exposed	17 / 64 (26.56%)	6 / 34 (17.65%)	16 / 40 (40.00%)
occurrences (all)	22	22	23
Palatal ulcer			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	0	0	2
Vomiting			
subjects affected / exposed	13 / 64 (20.31%)	3 / 34 (8.82%)	8 / 40 (20.00%)
occurrences (all)	19	9	12
Stomatitis			
subjects affected / exposed	1 / 64 (1.56%)	3 / 34 (8.82%)	5 / 40 (12.50%)
occurrences (all)	1	3	6
Dry mouth			
subjects affected / exposed	3 / 64 (4.69%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	3	0	1
Toothache			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	1	0	0
Eructation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0

Odynophagia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Cheilitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	0 / 40 (0.00%)
occurrences (all)	0	1	0
Anal haemorrhage			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	1	0	0
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	1 / 40 (2.50%)
occurrences (all)	0	1	1
Dermatitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	2	0	0
Nail ridging			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	8 / 40 (20.00%)
occurrences (all)	1	0	11
Eczema			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	0	0	2
Dry skin			
subjects affected / exposed	6 / 64 (9.38%)	1 / 34 (2.94%)	12 / 40 (30.00%)
occurrences (all)	6	1	16
Dermatitis contact			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
<b>Dermatitis acneiform</b>			
subjects affected / exposed	18 / 64 (28.13%)	2 / 34 (5.88%)	11 / 40 (27.50%)
occurrences (all)	20	2	13
<b>Onychoclasia</b>			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	3 / 40 (7.50%)
occurrences (all)	0	0	3
<b>Palmar-plantar erythrodysesthesia syndrome</b>			
subjects affected / exposed	1 / 64 (1.56%)	3 / 34 (8.82%)	5 / 40 (12.50%)
occurrences (all)	1	3	5
<b>Photosensitivity reaction</b>			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	9 / 40 (22.50%)
occurrences (all)	0	0	10
<b>Pruritus</b>			
subjects affected / exposed	7 / 64 (10.94%)	1 / 34 (2.94%)	5 / 40 (12.50%)
occurrences (all)	14	1	5
<b>Rash</b>			
subjects affected / exposed	28 / 64 (43.75%)	0 / 34 (0.00%)	13 / 40 (32.50%)
occurrences (all)	33	0	17
<b>Rash erythematous</b>			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	3 / 40 (7.50%)
occurrences (all)	0	0	4
<b>Rash macular</b>			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	0	0	3
<b>Skin disorder</b>			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	0	0	2
<b>Skin fissures</b>			
subjects affected / exposed	1 / 64 (1.56%)	1 / 34 (2.94%)	7 / 40 (17.50%)
occurrences (all)	1	1	11
<b>Skin toxicity</b>			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	4 / 40 (10.00%)
occurrences (all)	0	0	7

Decubitus ulcer			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Dermal cyst			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Rosacea			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	3 / 64 (4.69%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	3	0	1
Erythema nodosum			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Hair texture abnormal			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Skin exfoliation			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	0	0	1
Hand dermatitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Acne			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	0	0	2
Urticaria			
subjects affected / exposed	3 / 64 (4.69%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	5	0	0
Renal and urinary disorders			
Dysuria			

subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	2	0	0
Proteinuria			
subjects affected / exposed	1 / 64 (1.56%)	2 / 34 (5.88%)	1 / 40 (2.50%)
occurrences (all)	1	4	1
Renal colic			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	0	0	1
Nephrolithiasis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hyperthyroidism			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	1	0	0
Hypothyroidism			
subjects affected / exposed	3 / 64 (4.69%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	3	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	8 / 64 (12.50%)	3 / 34 (8.82%)	18 / 40 (45.00%)
occurrences (all)	8	5	30
Back pain			
subjects affected / exposed	5 / 64 (7.81%)	3 / 34 (8.82%)	5 / 40 (12.50%)
occurrences (all)	5	3	5
Bone pain			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	1	0	2
Pain in extremity			
subjects affected / exposed	5 / 64 (7.81%)	2 / 34 (5.88%)	7 / 40 (17.50%)
occurrences (all)	6	2	10
Musculoskeletal chest pain			

subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	0	0	2
Myalgia			
subjects affected / exposed	5 / 64 (7.81%)	2 / 34 (5.88%)	6 / 40 (15.00%)
occurrences (all)	5	3	8
Muscle tightness			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	1	0	0
Osteoporosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	0	0	1
Osteoporotic fracture			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	2 / 64 (3.13%)	1 / 34 (2.94%)	3 / 40 (7.50%)
occurrences (all)	2	1	3
Eye infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	1 / 40 (2.50%)
occurrences (all)	0	1	1
Nasopharyngitis			
subjects affected / exposed	3 / 64 (4.69%)	1 / 34 (2.94%)	1 / 40 (2.50%)
occurrences (all)	4	1	1
Onychomycosis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0

Folliculitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	6 / 40 (15.00%)
occurrences (all)	0	0	8
Paronychia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	5 / 40 (12.50%)
occurrences (all)	0	0	13
Rhinitis			
subjects affected / exposed	1 / 64 (1.56%)	3 / 34 (8.82%)	0 / 40 (0.00%)
occurrences (all)	1	3	0
Tracheitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	7 / 64 (10.94%)	1 / 34 (2.94%)	1 / 40 (2.50%)
occurrences (all)	10	1	1
Upper respiratory tract infection			
subjects affected / exposed	2 / 64 (3.13%)	3 / 34 (8.82%)	3 / 40 (7.50%)
occurrences (all)	2	3	4
Gastroenteritis			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	2	0	0
Staphylococcal infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Vascular device infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Febrile infection			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	0 / 40 (0.00%)
occurrences (all)	0	1	0
Catheter site infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Device related infection			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	0	0	2

Vulvitis			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Anal abscess			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	1	0	0
Metabolism and nutrition disorders			
Food craving			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	11 / 64 (17.19%)	1 / 34 (2.94%)	8 / 40 (20.00%)
occurrences (all)	12	1	10
Hyperglycaemia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	1 / 40 (2.50%)
occurrences (all)	1	0	1
Hypoalbuminaemia			
subjects affected / exposed	1 / 64 (1.56%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	1	0	0
Hypocalcaemia			
subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	2	0	3
Hypomagnesaemia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	6 / 40 (15.00%)
occurrences (all)	0	0	6
Hypophosphataemia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	2 / 40 (5.00%)
occurrences (all)	0	0	2
Hypokalaemia			
subjects affected / exposed	4 / 64 (6.25%)	1 / 34 (2.94%)	3 / 40 (7.50%)
occurrences (all)	4	1	6
Dehydration			



subjects affected / exposed	2 / 64 (3.13%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	2	0	0
Hyperkalaemia			
subjects affected / exposed	0 / 64 (0.00%)	1 / 34 (2.94%)	0 / 40 (0.00%)
occurrences (all)	0	1	0
Hypercalcaemia			
subjects affected / exposed	0 / 64 (0.00%)	0 / 34 (0.00%)	0 / 40 (0.00%)
occurrences (all)	0	0	0

<b>Non-serious adverse events</b>	Cohort 3 (IP)		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 6 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Melanocytic naevus			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Cancer pain			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Tumour associated fever			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Hypotension			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Phlebitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Face oedema			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		

Asthenia			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	4 / 6 (66.67%)		
occurrences (all)	6		
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Mucosal inflammation			
subjects affected / exposed	3 / 6 (50.00%)		
occurrences (all)	3		
Pain			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Pyrexia			
subjects affected / exposed	2 / 6 (33.33%)		
occurrences (all)	2		
Oedema peripheral			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Catheter site pain			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
General physical health deterioration			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Malaise			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			

Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Dysphonia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Pulmonary embolism			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Nasal ulcer			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Nasal dryness			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	3 / 6 (50.00%)		
occurrences (all)	3		
Hiccups			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Insomnia			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Product issues			
Device occlusion			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Amylase increased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Ejection fraction decreased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Blood creatinine increased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Blood bilirubin increased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Lipase increased			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Neutrophil count decreased			
subjects affected / exposed	2 / 6 (33.33%)		
occurrences (all)	2		
Platelet count decreased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Weight increased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Weight decreased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Cardiac murmur			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Blood potassium decreased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
C-reactive protein increased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Body temperature increased			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
White blood cell count decreased			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Injury, poisoning and procedural complications			

Infusion related reaction			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Lumbar vertebral fracture			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Sunburn			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Gastrointestinal stoma complication			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Stoma site pain			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Wound dehiscence			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dysgeusia			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Headache			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Peripheral motor neuropathy			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Neurotoxicity			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Paraesthesia			

subjects affected / exposed	2 / 6 (33.33%)		
occurrences (all)	2		
Neuropathy peripheral			
subjects affected / exposed	2 / 6 (33.33%)		
occurrences (all)	2		
Peripheral sensory neuropathy			
subjects affected / exposed	3 / 6 (50.00%)		
occurrences (all)	7		
Polyneuropathy			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Restless legs syndrome			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Somnolence			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Taste disorder			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Sensory loss			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Ageusia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Leukopenia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		

Thrombocytopenia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Ear and labyrinth disorders Auditory meatus external erosion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Eye disorders Cataract subjects affected / exposed occurrences (all)  Conjunctival haemorrhage subjects affected / exposed occurrences (all)  Lacrimation increased subjects affected / exposed occurrences (all)  Periorbital oedema subjects affected / exposed occurrences (all)  Dry eye subjects affected / exposed occurrences (all)  Visual impairment subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  1 / 6 (16.67%) 1		
Gastrointestinal disorders Angular cheilitis subjects affected / exposed occurrences (all)  Abdominal pain subjects affected / exposed occurrences (all)  Abdominal pain upper subjects affected / exposed occurrences (all)  Constipation	0 / 6 (0.00%) 0  1 / 6 (16.67%) 1  0 / 6 (0.00%) 0		



subjects affected / exposed	2 / 6 (33.33%)		
occurrences (all)	2		
Dental cyst			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	4 / 6 (66.67%)		
occurrences (all)	9		
Haemorrhoids			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dysphagia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Gingival bleeding			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	2 / 6 (33.33%)		
occurrences (all)	2		
Palatal ulcer			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Rectal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Vomiting			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	2		
Stomatitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dry mouth			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Toothache			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Eructation			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Odynophagia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Cheilitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Anal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Hepatomegaly			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Dermatitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Nail ridging			

subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Erythema			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Eczema			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Dermatitis contact			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dermatitis acneiform			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Onychoclasia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	4 / 6 (66.67%)		
occurrences (all)	7		
Photosensitivity reaction			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Rash			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Rash erythematous			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		

Rash macular			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Skin disorder			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Skin fissures			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Skin toxicity			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Decubitus ulcer			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Dermal cyst			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Rosacea			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Rash maculo-papular			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Erythema nodosum			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hair texture abnormal			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Skin exfoliation			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Hand dermatitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		

Blister subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Acne subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Urticaria subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0		
Renal and urinary disorders Dysuria subjects affected / exposed occurrences (all)  Proteinuria subjects affected / exposed occurrences (all)  Renal colic subjects affected / exposed occurrences (all)  Nephrolithiasis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0  0 / 6 (0.00%) 0		
Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all)  Hypothyroidism subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0  0 / 6 (0.00%) 0		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)  Back pain subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1  0 / 6 (0.00%) 0		

Bone pain			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Muscle spasms			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Musculoskeletal chest pain			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Muscle tightness			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Muscular weakness			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Osteoporosis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Osteoporotic fracture			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Eye infection			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Oral herpes			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Onychomycosis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Folliculitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Paronychia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Rhinitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Tracheitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Gastroenteritis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Staphylococcal infection			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Vascular device infection			

subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Febrile infection			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Catheter site infection			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Device related infection			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Vulvitis			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Anal abscess			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Cystitis			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Food craving			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Decreased appetite			
subjects affected / exposed	2 / 6 (33.33%)		
occurrences (all)	2		
Hyperglycaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hypoalbuminaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hypocalcaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		



Hypomagnesaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hypophosphataemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	1 / 6 (16.67%)		
occurrences (all)	1		
Dehydration			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hyperkalaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		
Hypercalcaemia			
subjects affected / exposed	0 / 6 (0.00%)		
occurrences (all)	0		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
30 November 2015	Changes include the replacement of terms "MPDL3280A" and "MPDL3280A (anti-PD-L1 antibody)" with "atezolizumab" (international, non-proprietary name); revision of study eligibility criteria to allow patients with cerebellar metastases, exclude patients with progression of CNS disease between last CNS-directed therapy and study baseline prior to baseline, exclude patients requiring steroid therapy for CNS disease; revision of Cohort 2 eligibility criteria to exclude patients continuing RANKL inhibitor therapy; clarifications and updates on drug products; updates to address any safety concerns or knowledge gaps; and other minor details.
11 April 2016	Changes include increasing the Cohort 2 target sample size from 330 to 405 patients to increase statistical power for Cohort 2 analyses and accommodate rapid accrual into Cohort 2. As a result of this change, the estimated duration of the study for Cohort 2 was increased from 17 to 22 months and the estimated overall study accrual was increased from 610 to 700 patients.
24 November 2016	Changes include Cohort 2 closure due to completion of accrual; incorporation of two new cohorts (Cohort 3: capecitabine/trastuzumab/pertuzumab vs fluoropyrimidine/bevacizumab in HER2+ patients; Cohort 4: cobimetinib/atezolizumab vs fluoropyrimidine/bevacizumab in HER2-/MSI-H; HER2-/MSS/BRAFwt or HER2-/MSS/BRAFmut/RASmut patients); adaptation of cohort assignment decision tree and study length estimates to accommodate new cohorts and Cohort 2 closure; removal of co-primary endpoint "early efficacy during the Maintenance Treatment Phase" based on advisory committees' advice (PFS remains as single primary efficacy endpoint); optional stool sample collection added to address a new exploratory microbiome biomarker evaluation objective; preliminary assessments of efficacy in each cohort removed based on advisory committees' advice; maximum allowable 5-FU dosing in Cohort 1 increased to 2,400 mg/m <sup>2</sup> based on completion of safety run-in review by the iDMC; local ablation for liver metastases now allowed during the induction treatment phase; second-line treatment for BRAFmut early progressors modified to 5-FU/vemurafenib/cetuximab for BRAFmut/MSS patients and FP/bevacizumab/atezolizumab for BRAFmut/MSI-H patients; updates to cohort-specific exclusion criteria, safety monitoring, and treatment management based on current safety data. Country specific protocols versions introduced for Spain and France due to jurisdictional requirements for safety monitoring and for Egypt and the UK where Cohorts 3 and 4 were not opened (study enrolment closed in Egypt and UK).
08 August 2018	In accordance with independent Data Monitoring Committee recommendations following review of safety data, accrual into Cohort 4 was closed.
19 December 2019	Enrolment into study was closed. Cohort 4 (now closed due to iDMC recommendations) had broad biomarker eligibility criteria and was introduced to replace Cohort 2 (previously closed due to completion of accrual). No new or modified cohorts with broad eligibility criteria suitable for addition to protocol MO29112 were identified. Without a broad eligibility cohort to replace Cohort 4, the majority of patients eligible for study entry would not be eligible for any maintenance cohort assignment upon completion of study induction treatment. For this reason, the Sponsor decided to permanently discontinue enrolment.
18 February 2020	Changes include updates to safety information and treatment management for patients receiving atezolizumab; update to responsible Medical Monitor.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
12 February 2018	Following the iDMC review of cohort 4 data a temporary recruitment halt to the whole study and a temporary halt to randomisation into cohort 4 was undertaken.	08 August 2018

Notes:

### Limitations and caveats

None reported